L-asparaginase production review: bioprocess design and biochemical characteristics

Daniel Castro¹, Ana Sofia C. Marques¹, Mafalda R. Almeida¹, Gabriela B. de Paiva², Heitor B. S. Bento², Danielle B. Pedrolli², Mara G. Freire¹, Ana P. M. Tavares¹* and Valéria C. Santos-Ebinuma²*

¹CICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
²Department of Bioprocess Engineering and Biotechnology, School of Pharmaceutical Sciences, UNESP- São Paulo State University, Araraquara, Brazil

ORCID of the authors:
Daniel Castro: 0000-0003-0804-4000
Ana Sofia Marques: 0000-0001-5798-0917
Mafalda R. Almeida: 0000-0003-2101-8309
Gabriela B. de Paiva: 0000-0003-2084-4895
Heitor B. S. Bento: 0000-0002-0629-3196
Danielle B. Pedrolli: 0000-0002-3034-6497
Mara G. Freire: 0000-0001-8895-0614
Ana P. M. Tavares: 0000-0001-9128-6275
Valéria C. Santos-Ebinuma: 0000-0002-6666-6695

*Corresponding authors:
Valéria C. Santos-Ebinuma:
e-mail: valeria.ebinuma@unesp.br
Ana P. M. Tavares:
e-mail: aptavares@ua.pt
Abstract

In the past decades, production of biopharmaceuticals has gained high interest due to its high sensitivity, specificity and lower risk of negative effects to patients. Biopharmaceuticals are mostly therapeutic recombinant proteins produced through biotechnological processes. In this context, L-Asparaginase (L-Asparagine amidohydrolase, L-ASNase (E.C. 3.5.1.1)) is a therapeutic enzyme that has been abundantly studied by researchers due to its antineoplastic properties. As a biopharmaceutical, L-ASNase has been used in the treatment of acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML) and other lymphoid malignancies, in combination with other drugs. Besides its application as a biopharmaceutical, this enzyme is widely used in food processing industries as an acrylamide mitigation agent and as a biosensor for the detection of L-Asparagine in physiological fluids at nano-levels. The great demand for L-ASNase is supplied by recombinant enzymes from *Escherichia coli* and *Erwinia chrysanthemi*. However, production processes are associated to low yields and proteins associated to immunogenicity problems, which leads to the search for a better enzyme source. Considering the L-ASNase pharmacological and food importance, this review provides an overview of the current biotechnological developments in L-ASNase production and biochemical characterization aiming to improve the knowledge about its production.

Key points

- Microbial enzyme applications as biopharmaceutical and in food industry
- Biosynthesis process: from the microorganism to bioreactor technology
- Enzyme activity and kinetic properties: crucial for the final application

Keywords

L-Asparaginase, Biopharmaceutical, Food industry, Bioprocess.
Introduction

Recent advances in enzyme technology empowers the scientists to use, modify and improve the efficiency of enzymes leading to a maximum functionality and high value are obtained (Muneer et al. 2020). L-Asparaginase (L-Asparagine amidohydrolase, L-ASNase) (EC 3.5.1.1) has been extensively used and studied because of its relevant potential as an oncological agent and as an acrylamide mitigation agent in the food industry due to its ability to catalyze the hydrolysis of L-Asparagine into L-aspartate and ammonia (Sharma et al. 2018; Chand et al. 2020). The discovery and development of potential uses of L-ASNase as an anti-cancer drug started in 1953, when Kidd first observed that lymphomas in rat and mice relapsed after treatment with guinea pig serum (Kidd 1953). Nowadays, L-ASNase is widely used in the treatment of acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML) and other lymphoid malignancies in combination with other drugs (Husain et al. 2016; Vala et al. 2018). However, formulations of this protein represents 40% of the total enzyme demands worldwide and one-third of the global needs for anticancer agents, which is far more than other therapeutic enzyme (Izadpanah et al. 2018). The biopharmaceutical world market, especially the healthcare market, is constantly growing. Therapeutical enzymes market was expected to reach $6.3 billion by 2021 as compared to $5.0 billion in 2016, corresponding to a 4.7% annual growth rate for the period (Chand et al., 2020).

Moreover, L-ASNase is widely used in food processing industries as an acrylamide mitigation agent since this compound is being classified as a probable carcinogen compound according to several agencies, namely the International Agency for Research on Cancer (Javier et al. 2016). Additionally, L-ASNase biosensor is a promising technology for the detection of L-Asparagine in physiological fluids at nano-levels (Batool et al. 2016).
Several microorganisms and even a few plants and animals endowed with L-ASNase producing ability. However, due to the complex process of extracting and purifying enzymes from plants and animals, the use of microorganisms is the most viable alternative (Moguel 2018). For instance, all L-ASNase drugs commercially authorized for clinical purposes are restricted to recombinant L-ASNase from *Escherichia coli* and *Erwinia chrysanthemi* (Muneer et al. 2020). Moreover, in order to have commercial and therapeutic value, L-ASNase must be stable over a wide range of pH and temperature, must have a low Michaelis-Menten constant ($K_m$) value (high substrate affinity in physiological conditions) and low collateral effects (Chand et al. 2020). Therefore, several investigations have been carried out in order to produce recombinant L-ASNase with improved characteristics and properties. Figure 1 presents an overview of L-ASNase production by recombinant microorganisms.

Figure 1. Overview of L-Asparaginase production by recombinant microorganisms.

Fig. 1
This review provides a deep overview of the literature regarding the microbial production of L-ASNase using different strategies, as well as its biochemical characterization.

**Classification of L-Asparaginase**

Although L-ASNase can be produced by several sources, this enzyme is classified based on its amino acid sequence, biochemical properties and structural and functional homology (Müller and Boos 1998). Currently, L-ASNases are divided into three major groups: (i) Bacterial-types L-ASNase (including the classification type I and type II), (ii) Plant-types L-ASNase (type III), and (iii) Rhizobial types L-ASNase (Borek and Jaskólski 2001; Qeshmi et al. 2018). Bacterial-types L-ASNases are structurally and evolutionarily distinct from the plant-type (Michalska and Jaskolski 2006). The bacterial-types L-ASNase are subdivided in type I and II based on their cellular localization and on the activity towards L-Asparagine and L-Glutamine (Izadpanah et al. 2018). L-ASNase type I is a cytosolic enzyme with relatively low affinity for L-Asparagine and high specific activity towards L-Glutamine. On the other hand, type II is a periplasmic or membrane associated L-ASNase with high affinity for L-Asparagine and low activity towards L-Glutamine, a combination highly attractive for oncologic application (Izadpanah et al. 2018). Both types of L-ASNase can be produced by the same microorganism, for example, *E. coli* is able to produce two isozymes of L-ASNase (Qeshmi et al. 2018), however, only the L-ASNase type II possesses anti-tumor activity. The characteristics of bacterial L-ASNase type I and type II are summarized in the Figure 2.
Figure 2. Mainly characteristics of bacterial L-Asparaginase type I and type II.

The structural feature differentiating type I and II isoenzymes is the active complex size. L-ASNase type-I seems to form dimers (Yao et al., 2005; Yano et al., 2008), whereas the L-ASNase type-II is widely reported as a tetramer. According to Aghaiypour et al. (2001) and Lubkowski et al. (2003) bacterial L-ASNases type II are active as homo-tetramers with 222 symmetry, each monomer consisting of about 330 amino acid residues forming 14 β-strands and eight α-helices as shown in Figure 3 for the three-dimensional structure of E. chrysanthemi L-ASNase type-II (Lubkowski et al. 2003). Studies on L-ASNase type-I structure are much scarcer in the literature than those of type-II.
Figure 3. Three-dimensional structure of *Erwinia chrysanthemi* L-Asparaginase type II suggested Aghaiypour et al. (2001) and Lubkowski et al. (2003).

It is also important to discuss the structure of L-ASNase at molecular levels. Commonly, the enzyme is found as a tetramer, but monomeric, dimeric and hexameric forms have also been found for enzymes isolated from different sources (Batool et al. 2016). In fact, molecular structures of L-ASNases from *E. coli* and *Erwinia sp.* have been deeply investigated. The native L-ASNase type II isolated from *E. coli* has a molecular weight of 138-141 kDa and contains four identical subunits of 326 amino acids with one active center each (Kozak and Jurga 2002). The reported molecular weight of the *Erwinia*-derived L-ASNase is 138 kDa as described in Table 1 (Nguyen et al., 2016; Müller and Boos 1998). Information about the kinetic parameters of this L-ASNase formulations is also presented at Table 1. Different sources and post-translation modifications may strongly influence the molecular structure of the enzyme. For instance, Asselin et al. (1995) reported a PEG modified L-ASNase from *E. coli* with increased half-lifetime (5-7 days) and molecular weight of 145 kDa.
Table 1. Properties of different L-Asparaginase preparations.

| Source        | Molecular weight (kDa) | Isoelectric point (pI) | Kᵢ (μM) Asparagine | Kᵢ (mM) Glutamine | Half lifetime | Reference                  |
|---------------|------------------------|------------------------|---------------------|-------------------|---------------|-----------------------------|
| *E. chrysanthemi* | 138                   | 8.7                    | 12                  | 1.10              | 8-22 h        | (Nguyen et al. 2016)        |
| *E. coli*     | 141                   | 5                      | 10                  | 6.25              | 8-30 h        | (Asselin et al. 1995)       |
| PEG-*E. coli* | 145                   | 5                      | 10                  | nd                | 5-7 days      | (Asselin et al. 1995)       |
| *B. subtilis 168* | 40                    | MD*                    | 5290                | nd                | 1 h           | (Feng et al. 2017)          |

nd: not determined.

The stability and half-lifetime of L-ASNase in the serum are of crucial concern for the pharmaceutical industry. An enzyme preparation with high stability and increased half-lifetime can avoid the need for multiple dose administration, which may lead to less chances of triggering hypersensitivity reactions (Krishnapura et al. 2016). Therefore, from the different L-ASNases analyzed for clinical trials, the ones from *E. coli* modified with PEG revealed a higher half-life when compared to non-modified *E. coli* L-ASNase, which ensure adequate serum enzyme activity and prevents complete L-ASNase serum depletion (Pieters et al. 2011, Asselin et al., 1995). An often used modification to prevent hypersensitivity reactions toward the native forms of L-ASNase is the PEG conjugation (Müller and Boos 1998; Pui et al. 2018). For preparation of the modified enzyme, units of monomethoxy PEG are attached to the derived enzyme (e.g. *E. coli*) by covalent bonds (Yoshimoto et al. 1986).

**Sources of L-Asparaginase**

*Production of L-Asparaginase by wild type species*

As cited previously, L-ASNase is widely distributed in nature, being found in animals (fishes, mammals and birds), in different tissues (such as liver, pancreas, brain,
kidneys and lungs), plants and microorganisms, including bacteria, filamentous fungi and yeast (Lopes et al. 2017; Brumano et al. 2019). However, as indicated by Savitri and Wamik, microorganisms are a better source of L-ASNase, considering their ability to grow easily on very simple and economical substrates (Savitri et al. 2003). Additionally, the biotechnological production process is usually easier to optimize and scale-up than other processes. Depending on the strain employed, it can be easily genetic modified in order to increase the yield, making the extraction and purification process economically feasible (Lopes et al. 2017).

Table 2 shows several microbial wild-type species able to produce L-ASNase and the corresponding enzyme characteristics. The best producers of L-ASNase belong to the Enterobacteriaceae family, followed by fungi species. The main bacteria producers of L-ASNase are *E. coli* and *E. chrysanthemi*. However, the main problem associated with L-ASNase produced by prokaryotic microorganism are hypersensitivity and immune inactivation (Javier et al. 2016). In this sense, different strategies with bacterial source have been studied and it will be further discussed in the section Production of recombinant L-Asparaginase. Considering the production process, the L-ASNase produced by *E. coli* is intracellular, which insert one unit operation in the downstream processes. Actinomycetes are filamentous bacteria well known as a good source of antibiotics and these microorganisms such as *Sreptomyces griseoluteus*, *Nocardia levis* and *Streptomyces ginsengisoli* were also reported to be potential producers of L-ASNase (Orabi et al. 2019; Qeshmi et al. 2018). The L-ASNase produced by actinomycetes is generally extracellular, which is an advantage for the production process. Saxena et al. (2015) studied 240 actinomycetes being 165 positives for L-ASNase activity. Among them, the strains *S. cyaneus* (SAP 1287, CFS 1560), *S. exfoliates* (CFS 1557) and *S. phaeochromogenes* (GS 1573) were L-Glutaminase-free actinomycetes with a
highlighted production of glutaminase free L-ASNase by the last strain (Saxena et al. 2015). However, studies performed by Dhevagi and Poorani (2006) showed that L-ANSase from marine actinomycetes presented cytotoxic effect on acute T-cell leukemia and myelogenous leukemia (Dhevagi and Poorani 2006) being this source of L-ASNase an alternative for the food industry.

Fungal L-ASNases are commonly produced extracellularly, easing the downstream purification process (Chand et al. 2020). Fusarium, Aspergillus, and Penicillium strains are the most common fungi genera reposted to produce L-ASNase (Orabi et al. 2019). L-ASNases from Aspergillus oryzae and Aspergillus niger are already commercially approved for use as processing agents in the food industry (Chand et al. 2020). The health sector requires a nobler source of L-ASNase with minimal or no cross-reactivity to minimize adverse reactions. Alike human cells and unlike bacterial cells, fungi cells can glycosylate proteins; therefore, enzymes isolated from fungi are expected to cause less immunogenicity (Chand et al. 2020). However, the fungal complex morphology can be critical for the feasibility of scaling up the process since fungal cultivation in bioreactor are sensible to several parameters such as oxygen supply and transfer, inoculum size, pH and stirring (De Oliveira et al., 2020).

Several yeast genera (Table 2) including Saccharomyces, Candida, Pichia, Rhodotorula, Rhodosporidium, and Trichoderma have been reported as L-ASNase producers (Chand et al. 2020; Kil et al., 1995; Foda et al., 1980). S. cerevisiae strains were found to produce both the intracellular and extracellular forms of L-ASNase, whereas production of the extracellular form seems to be triggered under nitrogen starvation (Sharma et al. 2018).

An alternative source of L-ASNase is blue-green microalgae, an attractive option due to its no seasonal variation, low cost of medium formulation, and easy cultivation and
harvesting characteristics (Orabi et al. 2019). *Chlamydomonas sp., Chlorella vulgaris, Spirulina maxima*, are considered as potential microalgal sources for novel enzymes production in several studies (Orabi et al. 2019; Ebrahiminezhad et al., 2014; Abd El-Baky and El-Baroty, 2016).
Table 2. Microbial wild-type species producer of L-ASNase and corresponding properties

| Microorganism | Strain                  | Localization | $K_{m}$ (µM) | $k_{cat}$ (s$^{-1}$) | $V_{max}$                  | Reference                                      |
|---------------|-------------------------|--------------|--------------|------------------|---------------------------|------------------------------------------------|
| Bacteria      | *Bacillus licheniformis*| Extracellular| 14           | $2.68 \times 10^{3}$| 4.03 IU                  | (Mahajan et al. 2014)                         |
| Bacteria      | *Bacillus sp.*          | Extracellular| nd           | nd               | nd                         | (Singh and Srivastava 2012)                   |
| Bacteria      | *Serratia marcescens*   | Intracellular| 100          | nd               | nd                         | (Boyd and Phillips 1971)                      |
| Bacteria      | *Vibrio succinogenes*   | Intracellular| 17           | nd               | nd                         | (Kafkewitz and Goodman 1974)                  |
| Bacteria      | *Erwinia carotovora*    | Intracellular| 96           | nd               | 1632.6 µmol mg$^{-1}$ min$^{-1}$ | (Warangkar and Kho bragade 2010)             |
| Algae         | *Chlamydomonas species*| Intracellular| 134          | nd               | nd                         | (Paul 1982)                                   |
| Algae         | *Spirulina maxima*      | Intracellular| nd           | nd               | nd                         | (Abd El Baky and El Baroty 2016)              |
| Actinomycete  | *Streptomyces phaeochromogenes* | Extracellular | nd | nd | nd | (Saxena et al. 2015) |
| Fungi         | *Aspergillus niger*     | Extracellular| 16           | nd               | 66.66 µM mL$^{-1}$ min$^{-1}$ | (Luhana et al. 2013)                         |
| Fungi         | *Aspergillus terreus*   | Extracellular| nd           | nd               | nd                         | (Farag et al. 2015)                          |
| Fungi         | *Cladosporium sp.*      | Extracellular| 100          | nd               | 4.00 µM mg$^{-1}$ min$^{-1}$ | (Mohan Kumar and Manonmani 2013)             |
| Fungi          | Expressed by                          | Condition     | Asparaginase Activity | Asparaginase Activity IU |
|---------------|--------------------------------------|---------------|------------------------|--------------------------|
| Penicillium sp.| Extracellular                        | $4.0 \times 10^3$ | nd                     | nd                       | (Patro 2012)              |
| Fusarium sp.  | Extracellular                        | $443.98 \times 10^3$ | nd                     | 40 IU                    | (Asha and Pallavi 2012)   |
| Candida utilis| Extracellular                        | nd            | nd                     | nd                       | (Kil et al. 1995)         |
| Pichia polymorpha | Extracellular                        | $13.7 \times 10^3$ | nd                     | nd                       | (Foda et al. 1980)        |
| Saccharomyces cerevisiae | Extracellular                        | nd            | nd                     | nd                       | (Dunlop and Roon 1975)    |

*nd: not determined. *International unit (IU) of asparaginase activity is defined as the amount of enzyme required to release one µmol of ammonia per minute at specified conditions.
As demonstrated, several microorganisms presenting particular characteristics can act as potential producers of L-ASNase. However, before designing and scaling up the bioprocess, pharmaceutical and food industry seeks for some characteristics, namely high productivity, easily handling and scaling up, highly stable enzymes (temperature, pH, storage), high enzymatic activity, low toxicity, easy product purification and low production costs (Chand et al., 2020; Brumano et al., 2019). Therefore, in-depth studies are essential to disclosure the best sources of the enzyme for industrial applications.

Production of recombinant L-Asparaginase

Recently, many efforts to produce recombinant L-ASNase from different sources have been made, as depicted in Table 3. Each system presents its own characteristics regarding production capacity, cost, safety, complexity and processing impact (Santos et al., 2018). It is important to highlight that in the last years there was significant progress in synthetic biology through the development of molecular tools and methods for engineering biological systems which facilitate the construction of efficient chassis for industrial relevant bioprocesses, including the production of L-ASNase (Corrêa et al., 2020). To exemplify, Corrêa et al. (2020) presented the engineering of tunable and modular devices for autonomous control of gene expression in B. subtilis that requires no inducer and no human supervision. The device developed can be applied for heterologous protein production (Corrêa et al. 2020).

The preferred host for overproduction of recombinant L-ASNase is E. coli, and the pET system with Isopropyl β-D-Thiogalactoside (IPTG) induction is the most used gene expression system (as summarized in Table 3). However, some work has been done
on alternative hosts such as *B. subtilis* (Feng et al. 2017; Sushma et al. 2017; Li et al. 2018) and *Pichia pastoris* (Sajitha et al. 2015; Rodrigues et al. 2019; Lima et al. 2020). Unlike *E. coli*, these hosts hold the GRAS (Generally Regarded as Safe) status, and can be engineered to secrete the enzyme to the medium, which may turn the downstream process easier and cheaper. From the gene sequence it is possible to establish that the *ansZ* gene from *B. subtilis* encodes a L-ASNase with 59% identity to the L-ASNase type I from *E. chrysanthemi* and 53% identity to the L-ASNase type II from *E. coli* (Fisher and Wray 2002). Moreover, *B. subtilis* has another gene (*ansA*) that encodes a L-ASNase type I (Yano et al. 2008). Feng et al. (2017) were able to successfully overproduce and secrete a recombinant L-ASNase type II in *B. subtilis*, reaching 2.5 g L\(^{-1}\) of enzyme in a 3 L bioreactor through a fed-batch strategy. More than protein secretion, *P. pastoris* is able to add post-translation modifications to the overproduced enzyme. Lima et al. (2020) used *P. pastoris* to engineer a L-ASNase with a human-like glycosylation pattern, which lowered the immunogenicity of the protein tested *in vitro* compared to the non-glycosylated.
Table 3

Table 3. Recombinant L-Asparaginase production and corresponding properties.

| Identification | Gene source          | Host                  | Plasmid            | Gene expression   | Localization   | $K_m$ (mM) | $k_{cat}$ (s$^{-1}$) | $V_{max}$       | Reference          |
|----------------|----------------------|-----------------------|--------------------|-------------------|---------------|------------|----------------------|-------------------|--------------------|
| L-ASNase type I| Acinetobacter soli  | *E. coli* BL21(DE3)  | pET30a             | IPTG-inducible    | Intracellular  | 3.22       | nd                   | 1.55 IU $\mu$g$^{-1}$ | (Jiao et al. 2020) |
| L-ASNase       | Anoxybacillus flavithermus | *E. coli* BL21-CodonPlus (DE3) | pET-22b (+) | IPTG-inducible | Intracellular | nd         | nd                   | nd                | (Maqsood et al. 2020) |
| L-ASNase       | Aspergillus terreus  | *E. coli* BL21(DE3)  | pET-28a (+)        | IPTG-inducible    | Intracellular  | nd         | nd                   | nd                | (Saeed et al. 2018a) |
| L-ASNase type II| Bacillus sp. SL-1   | *E. coli* BL21(DE3)  | pET22b+            | IPTG-inducible    | Intracellular  | 0.0103     | 23.96                | nd                | (Safary et al. 2019) |
| L-ASNase type II| Bacillus subtilis   | *B. subtilis* WB600  | pMA0911            | Constitutive      | Extracellular  | 5.3        | 54.4                 | nd                | (Feng et al. 2017)  |
| L-ASNase type II| Bacillus subtilis   | *B. subtilis* WB800N | pHT43              | IPTG-inducible    | Intracellular  | nd         | nd                   | nd                | (Sushma et al. 2017) |
| L-ASNase II    | Bacillus subtilis   | *B. subtilis* 168    | pMA5               | Constitutive      | Extracellular  | 0.43       | nd                   | 77.51 $\mu$M min$^{-1}$ | (Jia et al. 2013)   |
| L-ASNase       | Bacillus tequilensis| *E. coli* BL21 (DE3) | pET28a+            | IPTG-inducible    | Intracellular  | 0.07       | nd                   | 7.79 $\mu$M min$^{-1}$ | (Shakambari et al. 2018) |
| L-ASNase type II| Cobetia amphilectii| *E. coli* BL21 (DE3) | pQE80L             | IPTG-inducible    | Intracellular  | 2.05       | nd                   | 11641 $\mu$M min$^{-1}$ $mg^{-1}$ | (Farahat et al. 2020) |
| L-ASNase type | Organism | E. coli strain | Plasmid | Induction | Localization | Activity (U/mL) |
|---------------|----------|----------------|---------|-----------|--------------|----------------|
| L-ASNase      | *Erwinia carotovora* | BL21(DE3) | pET28a and pET22b | IPTG-inducible | Intracellular | nd             |
| L-ASNase type II | *Erwinia carotovora* | BL21 (DE3) | pET22b | IPTG-inducible | Intracellular | nd             |
| L-ASNase type II | *Erwinia chrysanthemi* | BL21 | pJ401; pM7L22p; pET14b | Constitutive | Intracellular | 0.029-0.080     |
| L-ASNase type II | *Escherichia coli* | BL21 | pMTL22p | Constitutive | Intracellular | 0.015-0.050     |
| L-ASNase type II | *Escherichia coli* | BL21 | pJAG-s1 | Methanol-inducible | Extracellular (wt), Periplasm (mut) | nd             |
| L-ASNase type II | *Lactobacillus casei* | BL21(DE3) | pET28a(+) | IPTG-inducible | Intracellular | 0.01235         |
| L-ASNase      | *Lactobacillus reuteri* | BL21(DE3) | pET28a(+) | IPTG-inducible | Intracellular | 0.3332          |
| L-ASNase      | *Nocardiopsis alba* | M15 | pQE30 | IPTG-inducible | Intracellular | nd             |
| L-ASNase      | *Paenibacillus barengoltzii* | BL21 (DE3) | pET-28a (+) | IPTG-inducible | Intracellular | 3.6             |
| L-ASNase type I | *Pseudomonas aeruginosa* | BL21 (DE3) | pET28a (+) | IPTG-inducible | Intracellular | nd             |

References:
- Faret et al. 2019
- Goswami et al. 2019
- Moola et al. 1994
- Gervais and Foote 2014
- Moola et al. 1994
- Derst et al. 2000
- Nguyen et al. 2016
- Lima et al. 2020
- Aishwarya et al. 2019
- Aishwarya et al. 2017
- Meena et al. 2016
- Shi et al. 2017
- Saeed et al. 2018b
| L-ASNase | Organism 1 | Organism 2 | Vector 1 | IPTG-inducible | Localization | Activity (μmol min⁻¹ mg⁻¹) |
|----------|------------|------------|----------|----------------|--------------|---------------------------|
| L-ASNase | *Pseudomonas fluorescens* | E. coli BL21(DE3) | pET-32a | IPTG-inducible | Intracellular | nd                         |
| L-ASNase | *Pseudomonas resinovorans* | E. coli rosetta DE3 | (+) | IPTG-inducible | Intracellular | nd                         |
| L-ASNase | *Pyrococcus furiosus* | E. coli BL21 (DE3) pLysS | pET26b (+) | IPTG-inducible | Intracellular | 1.623 105 μmol min⁻¹ mg⁻¹ |
| L-ASNase | *B. subtilis* 168 | pMA5 | Constitutive | Intracellular + Extracellular | 6.5 | 2929 μM min⁻¹ |
| L-ASNase type II | *Saccharomyces cerevisiae* | E. coli BL21(DE3) | pET28a(+) | IPTG-inducible | Intracellular | nd                         |
| L-ASNase | *Pichia pastoris* | pPIC9K | Methanol-inducible | Periplasmic | nd | nd |
| L-ASNase type II | *Vibrio cholerae* | E. coli BL21(DE3) | pET15b | IPTG-inducible | Intracellular | 0.075 217 0.042 μmol min⁻¹ |
| L-ASNase | *Streptomyces griseus* | E. coli M15 pREP4 | pQE30 | IPTG-inducible | Intracellular | nd                         |
| L-ASNase type II | *Thermococcus kodakarensis* | E. coli strain BL21-CodonPlus (DE3) | pET-21a | IPTG-inducible | Intracellular | 3.1 833 μmol min⁻¹ mg⁻¹ |
| L-ASNase type II | *Vibrio cholerae* | E. coli BL21 (DE3) | pMCSG7 | IPTG-inducible | Intracellular | 1.1 4424 1006 μM min⁻¹ |
| L-ASNase type II | Zymomonas mobilis | E. coli BL21 (DE3) | pET26a and pET28b | IPTG-inducible | Extracellular (pET26b); Intracellular (pET28a) | nd | nd | nd | (Einsfeldt et al. 2016) |
|------------------|-------------------|-------------------|-------------------|----------------|-----------------------------------------------|----|----|----|------------------------|

*nd: not determined. *International unit (IU) of asparaginase activity is defined as the amount of enzyme required to release one µmol of ammonia per minute at specified conditions.
Biochemical characterization of L-Asparaginase

Effect of pH and temperature in L-Asparaginase activity

In order to guarantee the best possible performance of an enzyme, biochemical characterization regarding temperature and pH are essential parameters to define its application (Krishnapura et al. 2016). Different studies have been performed in order to evaluate the effect of pH on L-ASNase activity produced by different microorganisms (Table 4). In general, the L-ASNase maximum activity ranges from acidic to alkaline pH values (Chand et al. 2020). The pH affects not only the enzyme structure but also its affinity for the substrate. For therapeutic use, optimal pH for the L-ASNase must lie in the physiological range, while for the food industry, the L-ASNase must keep enough activity even at acidic pH (Krishnapura et al. 2016). L-ASNase produced by bacteria such as *E. coli*, *B. megaterium* and *P. fluorescens* presents optimum activity at pH of 6.0, 7.0 and 7.5, respectively (Borah et al. 2012; Zhang et al. 2015; Sindhu and Manonmani 2018b). According to Kumar et al. (2020), a pH value close to 8.0 is needed for a maximum activity for L-ASNase from *B. subtilis*. The enzyme produced by *Penicillum sp.* and *A. flavithermus*, a fungus and a bacterium respectively, both demonstrate an optimal activity at pH of 7.0 (Chand et al. 2020; Maqsood et al. 2020). On the other hand, the Gram-negative bacteria *P. aeruginosa* PAO1 and *R. etli* produce enzymes with maximum activity in acidic and alkaline conditions, 5.5 and 9.0, respectively (Angélica et al. 2012; Dutta et al. 2015).

Temperature also affects the pace of catalysis and stability of an enzyme (Daniel et al. 2010). Temperature tolerance and stability of L-ASNases differs from species to species (Table 4); however, the enzymes often have optimal activity in a temperature range between 25 °C and 45 °C (Chand et al. 2020). Nevertheless, the extreme thermophiles *T. kodaka* (TK1656) and *T. kodaka* (TK2246) produce L-ASNases with
optimal activity at 85 °C (Chohan et al. 2020; Muneer et al. 2020). The study performed by Kumar et al. (2020), the authors concluded that the L-ASNase produced by B. subtilis shows an optimal activity at 37°C. Additionally, authors showed that this enzyme is also active in a wide range of temperature from 30 °C to 75 °C; yet, at the maximum temperature will eventually lead to an unstable enzyme with no application (Kumar et al. 2020). Similarly, Patro and Gupta (2012) obtained a L-ASNase from Penicillium sp with optimal activity at 37 °C. The authors determined the optimal temperature for the enzyme using a range of temperatures between 30 °C and 50 °C. The study performed by Borah et al. (2012), shows the production of L-ASNase from E. coli and the optimal enzyme activity was achieved at 55 °C. As well, on this study the authors defined that the enzyme produced was able to tolerate high temperatures and hence can be considered an thermostable enzyme (Borah et al. 2012).

One way to preserve and/or improve the enzyme characteristics including L-ASNase activity and stability is to confine or to immobilize the enzyme in nanomaterials. The process can enhance thermal, pH, storage and operational stabilities, and can even improve the pharmacological properties, as high enzyme selectivity. This modification process may also prevent enzyme deactivation (Nunes et al., 2020). Cristovão et al. (2020) studied the application of multi-walled carbon nanotubes (MWCNTs) as support for ASNase immobilization by adsorption method. According to the results, MWCNTs are efficient supports for ASNase immobilization, with no chemical modification or covalent binding required, opening up the possibility for ASNase–MWCNT bioconjugates in several application. L-ASNase immobilization and confinement techniques are interesting to maintain the enzyme biochemical properties.

Table 4
### Table 4. Optimum pH and Temperature of microbial L-Asparaginase.

| Microorganism                  | pH  | Temperature (ºC) | Reference                      |
|-------------------------------|-----|------------------|--------------------------------|
| Acinetobacter baumannii       | 7.2 | 37.0             | (Muslim 2014)                  |
| Anoxybacillus flavithermus    | 7.0 | 60.0             | (Maqsood et al. 2020)          |
| Aspergillus niger             | 6.5 | 40.0             | (Sharma et al. 2018)           |
| Aspergillus oryzae (CCT 3940) | 7.0-8.0 | 40.0     | (Dias et al. 2016)             |
| Bacillus subtilis             | 8   | 37.0             | (Kumar et al. 2020)            |
| Bacillus licheniformis        | 6.0-10.0 | 40.0       | (Mahajan et al. 2014)          |
| Bacillus megaterium           | 7.0 | 40.0             | (Zhang et al. 2015)            |
| Bacillus firmus (AVP 18)      | 9.0 | 37.0             | (Rudrapati and Audipudi 2015)  |
| Cobetia amphilecti AM16       | 7.0 | 60.0             | (Farahat et al. 2020)          |
| Corynebacterium glutamicum    | 7.0 | 40.0             | (Kumar and Sobha 2012)         |
| Escherichia coli              | 6.0 | 55.0             | (Borah et al. 2012)            |
| Penicillum sp                 | 7.0 | 37.0             | (Chand et al. 2020)            |
| Pseudomonas aeruginosa PAO1   | 5.5 | 50.0             | (Dutta et al. 2015)            |
| Pseudomonas fluorescens       | 7.5 | 37.0             | (Sindhu and Manonmani 2018)    |
| Stenotrophomonas maltophilia | 6.9 | 38.1             | (Abdelrazek et al. 2020)       |
| Streptomyces rochei           | 6.7 | 37.0             | (El-naggar and El-shweihy 2020)|
| Rhizobium etli                | 9.0 | 37.0             | (Angélica et al. 2012)         |
| Thermococcus kodaka (TK1656)  | 9.5 | 85.0             | (Muneer et al. 2020)           |
| Thermococcus kodaka (TK2246)  | 7.0 | 85.0             | (Chohan et al. 2020)           |
| Vibrio cholerae               | 7.1 | 38.5             | (Radha and Gummadi 2020)       |

**Influence of effector molecules on L-Asparaginase activity**

Metal ions are essential for the structural regulation of a protein as they act as electron donors or acceptors (Buchholz et al. 2012). In some cases, the presence of a metal ion is mandatory for the preservation of the multimeric structure of the enzyme and also to stabilize the reaction intermediates (Krishnapura et al. 2016). For a better understanding of the mechanism of enzyme action it is important that the influence of various effectors that activate or inhibit or in any other way affect the protein is well described and studied. These data may lead to catalytic efficiency improvement and
consequently a higher yield for biotechnological purpose of the enzyme (Krishnapura et al. 2016). In fact, the same metal chelator can have different influence on L-ASNase isolated from different sources. Ethylenediamine tetra acetic acid (EDTA) enhances the activity of the enzyme from *E. carotovora* but has no effect on the L-ASNase from *Cladosporium sp.* (Krishnapura et al. 2016). Divalent ions, such as Ca$^{2+}$, Co$^{2+}$, Cu$^{2+}$, Mn$^{2+}$, Hg$^{2+}$, Mg$^{2+}$, Fe$^{2+}$, Sn$^{2+}$, Pb$^{2+}$ and Ba$^{2+}$ were proved to have an inhibitory effect on L-ASNase from *Bacillus aryabhattai* ITHBHU02, while Na$^+$ and K$^+$ enhance the enzymatic activity (Singh et al. 2013). For L-ASNase from *Thermococcus gammatolerans* EJ3, Mg$^{2+}$ acts as an activator, while Zn$^{2+}$, Co$^{2+}$, Ca$^{2+}$, Mn$^{2+}$, Ni$^{2+}$, Cu$^{2+}$, and Ba$^{2+}$ are considered inhibitors of the enzyme (Zuo et al. 2014).

**Kinetic properties of L-Asparaginase**

The efforts to produce recombinant L-ASNases and the search for new different wild sources are mostly directed towards developing alternatives for treating ALL patients that develop hyper sensibility reactions to the available commercial L-ASNase. The underlining idea is that enzymes from different sources provide different protein sequences that may present different immunogenicity profiles. However, there are other requirements for a new enzyme to become an efficient new oncogenic biopharmaceutical, such as the kinetic parameters. Because L-asparagine is present at ~50 µM in the human blood, therapeutic L-ASNase must have a substrate affinity in the lower micromolar range (Ollenschläger et al. 1988; Nguyen et al. 2016). Low Michaelis-Menten constant ($K_m$) associated with high turnover number ($K_{cat}$) ensure that the therapeutic L-ASNase will sufficiently reduce the endogenous L-asparagine at safe doses (Beckett and Gervais 2019). Apart from this, kinetic parameters are crucial for the efficient use of enzymes in different industrial processes (Choi et al. 2017). Most of the mesophilic L-ASNase
reported to date have low $K_m$ values while the thermophilic ones show relatively high $K_m$ (Hong et al. 2014). The values of kinetic parameters for L-ASNases obtained from wild type and recombinant microorganisms are listed in Table 2 and Table 3, respectively.

In that regard, a few promising sources of recombinant enzymes were recently characterized: L-ASNase type II from *Lactobacillus casei* – $K_m$ 12.3 µM – (Aishwarya et al. 2019), L-ASNase A1 from *Bacillus* sp. SL-1 – $K_m$ 10.3 µM – (Safary et al. 2019), AnsA from *B. tequilensis* – $K_m$ 70 µM – (Shakambari et al. 2018), and ScASNase1 from *S. cerevisiae* – $K_m$ 75 µM – (Costa et al. 2016). These $K_m$ values closely match the *E. coli* ($K_m$ 10 µM) and the *E. chrysanthemi* ($K_m$ 12 µM) enzymes affinity for asparagine, as shown in Table 1, that present some L-ASNase characteristics of typical commercial sources (Krishnapura et al., 2016; Nguyen et al. 2016; Gervais and Foote 2014; Moola et al. 1994). Expressive high values of $K_{cat}$ were achieved by the recombinant L-ASNase from *Vibrio cholerae*, *S. cerevisiae*, and *E. chrysanthemi* (values ranging from 217 to 4424 s$^{-1}$). For comparison, commercial L-asparaginase Erwinase® and Elspar® present $K_{cat}$ around 286.2 s$^{-1}$ and 126.5 s$^{-1}$, respectively (Krishnapura et al., 2016).

Regarding wild type microorganism, several authors have reported L-ASNases with elevated substrate affinity, e.g. Warangkar and Khobragade (2010) produced an efficient enzyme from *Erwinia carotovora* presenting $K_m$ value of 0.096 mM. Elevated substrate affinity was also obtained by Mahajan et al. (2014) when studying the enzyme produced by *Bacillus licheniformis*, presenting a $K_m$ = 0.014 mM (Mahajan et al. 2014). For instance, Asha and Pallavi (2012) reported an enzyme from *Fusarium* sp. presenting $V_{max}$ = 40 IU and $K_m$ = 443.98 mM and indicated its potential in cancer therapy since the enzyme did not elicit any immunostimulatory response in human lymphocytes in vitro, unlike most of the reported prokaryotic asparaginases (Asha and Pallavi 2012). Enzymes generally present complex action mechanisms systems and need to be deeply studied.
before efficient and safe application. Kinect characterization has a key role in understanding enzymes activity and in designing the most efficient application routes. Additionally, as shown in Tables 2 and 3, the values of $K_m$ and $K_{cat}$ are intrinsically related to the enzyme source and represent important comparison parameters in order to evaluate the potential application of the protein.

**Bioprocess for L-Asparaginase production**

The effective application of a bioprocess for the production of the target enzyme requires a meticulously selection of the microorganism as the basis of the process, as it affects directly the characteristics of the final product (Brumano et al. 2019). Among the different species capable of producing L-ASNase and as previously mentioned, *E. coli* is the main microbial host used for the industrial-scale production of recombinant L-ASNase. However, other species have been studied and are promising candidates. L-ASNase production can be performed by submerged fermentation (SmF) and solid state fermentation (SSF) (Lopes et al. 2017). **Figure 4** summarizes the main advantages and limitation for both fermentation types of processes.

**Figure 4**
Figure 4. Comparison between submerged and solid-state fermentations for the production of L-ASNase. Adapted from Doriya et al. 2016.
SmF is the main type of fermentation employed for bacterial enzyme production and consequently, the most used to produce L-ASNase. In fact, SmF is well established and the manipulation of medium components is comparatively easier, leading to high production yields (Vimal and Kumar 2017). Moreover, no requirement for pre-treatment of substrate, easiness of manipulation of the reaction parameters and easy purification of products strongly contribute for the widely application of this type of fermentation. This type of fermentation allows the microorganism to grow in closed reactor containing a liquid broth medium. High concentration of dissolved oxygen is usually required. (Doriya et al. 2016).

As for other biomolecules, the process to obtain L-ASNase is considerably influenced by several factors, such as type and concentration of carbon and nitrogen sources, pH, temperature, fermentation time, aeration and mainly the microbial agent (Lopes et al. 2017). The productivity of microbial metabolites is related to the process variables such as type and concentrations of nutrients, and operation conditions (Marques et al., 2014). Submerged fermentations can be performed in laboratory scale (shaken flasks culture and bioreactor up to 10 L) and industrial scale (bioreactor larger than 10 L). The shaken flasks experiments are important to study the performance of microorganisms with minimal costs and material; therefore, it is extensively used to optimize some conditions for the biotechnological process, such as carbon and nitrogen source and concentration, microelements presence, among others. However, the production in shaker incubator presents several limitations such as limited oxygen transfer, and inability to control pH and dissolved oxygen tension. Moreover, for industrial application, high amounts of product is necessary and the production in bioreactor can improve the process reducing the product final cost (Gamboa-Suasnavart et al. 2013).
In bioreactor, the operation mode can generate high productivities. It can be carried out as batch (all nutrients required for the culture are added at the beginning of the cultivation and the product, by-products and non-consumed components are removed at the end of each batch), fed-batch (some nutrients are provided during the process until a limitation of volume, the product is removed at the end of each batch) and continuous fermentation (nutrients are added continuously, and product is removed at the same speed of the feeding flow, with the volume inside the bioreactor remaining constant) (Torres et al. 2016). Currently, there are several reports exploring the production of L-ASNase in shaken flasks and a few in bioreactor. However, with the market need for this enzyme, further studies in bioreactor are a bottleneck to be explored. Production of L-ASNase from various microbial sources by SmF and the respective optimized conditions reported in the literature are summarized in Table 5.
Table 5. L-asparaginase production by submerged culture at various operating conditions.

| Microorganism             | Culture medium type                          | Temperature (°C) | pH | Cultivation period (h) | Stirring (rpm) | L-ASNase activity | Reference                                      |
|---------------------------|----------------------------------------------|------------------|----|------------------------|----------------|--------------------|------------------------------------------------|
| **Spirulina maxima***     | Modified Zarrouk medium                      | 25               | 9.5| 432                   | -              | 51.28 IU L⁻¹      | (Abd El Baky and El Baroty 2016)               |
| **Enterobacter aerogenes**| Trisodium citrate (75%), Ammonium chloride (15%) | 33               | 6  | 40                    | -              | 18.35 IU mL⁻¹     | (Erva et al. 2017)                            |
| **Pectobacterium carotovorum** | Glucose (30 g/L), L-Asparagine (30 g/L) | 30               | 8.5| Feb-batch mode         | -              | 38.8 IU mL⁻¹      | (Chityala et al. 2015)                        |
| **Nocardia levis**       | Asparagine-glycerol salts (ISP-5) broth      | 30               | 7  | 72                    | -              | 5.06 ± .002 IU mg⁻¹ | (Kavitha and Vijayalakshmi 2012)               |
| **Aspergillus terreus**   | Czapek–Dox Medium+L-Asparagine 1%, yeast extract 1%, peptone 6%, glucose 4% | 35               | 6  | 72                    | 160            | 24.10 IU mL⁻¹     | (Gurunathan and Renganathan 2012)             |
| **Azotobacter vinelandii**| Succrose                                      | 30               | 7.4| -                     | -              | 4 IU mg⁻¹         | (Gaffar and Shethna 1977)                     |
| **Emericella nidulans**   | Czapek–Dox Medium                            | 30               | 6  | 48                    | -              | 1.1 IU            | (Jayaramu et al. 2010)                       |
| **E. coli**               | -                                            | 37               | 7.2| 24                    | 220            | 67 IU mg⁻¹        | (Khushoo et al. 2004)                         |
| **E. coli BL21***         | LB medium, Glucose 1%, kanamycin 50 µg/mL     | 37               | 7  | -                     | 200-800        | 3.6 IU mL⁻¹       | (Einsfeldt et al. 2016)                       |
| **E. coli K-12**          | Lactose; 10 g/L, Tryptone; 10 g/L, yeast extract; 5 g/L | 37               | 6.5| -                     | 200            | 3.82 IU mL⁻¹      | (Vimal and Kumar 2017)                        |
| Organism                                | Medium                        | L-Asparagine; 2 g/L and CaCl₂; 15 g/L | Tryptone, glucose, yeast extract broth | Tryptone, glucose, yeast extract broth | LB medium                        | Pseudomonas fluorescens Glucose, beef extract, L-Asparagine, salt solution | KH₂PO₄ 2.0, L-Asparagine 6.0, MgSO₄·7H₂O 1.0, CaCl₂·2H₂O 1.0 and glucose/maltose 3.0 | 37 | 7 | 24 | 200 | 1 IU mg⁻¹ | (Prema et al. 2013) |
|-----------------------------------------|-------------------------------|--------------------------------------|----------------------------------------|----------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----|---|----|-----|----------|-------------------|
| *Erwinia aroideae*                      |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Peterson and Ciegler 1969) |
| *Erwinia chrysanthemi 3937*             |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Kotzia and Labrou 2007) |
| *Erwinia carotova*                      |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Kotzia and Labrou 2005) |
| *Bacillus* sp. (DKMBT10)*               |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Moorthy, V; Ramalingam, A; Sumantha 2010) |
| *Pseudomonas fluorescens*               |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Prema et al. 2013) |
| *Acinetobacter glutaminasificans* (ATCC 27197)* |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Steckel et al. 1983) |
| *Bacillus aryabhattai ITBHU02*          |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Singh et al. 2013) |
| *Bacillus brevis*                       |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Narta et al. 2011) |
| *Bacillus licheniformis*                |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Alrumman et al. 2019) |
| *Bacillus subtilis hswx88*              |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Jia et al. 2013) |
| *Corynebacterium glutamicum*            |                               |                                      |                                        |                                        |                                   |                                                                                |                                                                                                                   |    |   |    |     |         | (Mesas et al. 1990) |
| **Marine actinomycetes S3** | TGY extract broth | 28  | 7  | 24  | 200 | 384.6 IU mg\(^{-1}\) | (Saleem Basha et al. 2009) |
|-------------------------------|------------------|-----|----|-----|-----|----------------------|--------------------------|
| **Penicillium brevicompactum** | Czapek–Dox Medium | -   | -  | -   | -   | 574.24 IU mg\(^{-1}\) | (Elshafei et al. 2014)   |
| **Pseudomonas stutzeri MB-405** | L-Asparagine and Na-succinate | 30  | 7  | 20  | 160 | 1.1 IU mg\(^{-1}\) | (Saleem Basha et al. 2009) |
| **Serratia marcescens**       | 4% (w/v) autolyzed yeast media | 26  | 5  | 40  | -   | 0.7 IU mg\(^{-1}\) | (Boyd and Phillips 1971) |
| **Serratia marcescens**       | Glycerol, peptone, yeast extract | 37  | 6.8-7.0 | 24 | -   | 2.4 IU mL\(^{-1}\) | (Sukumaran et al. 1979) |
| **Streptomyces brolosae NEAE-115** | Asparagine dextrose, starch | 37  | 7  | 168 | 150 | 9.79 IU mg\(^{-1}\) | (El-Naggar et al. 2018) |
| **Streptomyces noursei MTCC 10469** | Tryptone, glucose, yeast extract broth | 28  | 7  | 24  | 200 | 0.803 IU mg\(^{-1}\) | (Dharmaraj 2011) |
| **Streptomyces parvalus KUA 106** | Tryptone, glucose, yeast extract broth | 28  | 7  | 24  | -   | 146 IU mL\(^{-1}\) | (Usha et al. 2011) |
| **Vibrio succinogenes**       | Sodium fumarate, cysteine | 37  | 7.3-7.4 | -  | -   | -                   | (Krautheim et al. 1982) |
| **Vibrio succinogene**        | Succinate         | 37  | 7.0-7.2 | 18-22 | -         | 8.4 IU mg\(^{-1}\) | (Kafkewitz and Goodman 1974) |
| **Yersinia pseudotuberculosis YpA** | LB broth         | 37  | -   | -   | 150-180 | 8.7 IU mg\(^{-1}\) | (Pokrovskaya et al. 2012) |

*: Bioreactor experiments

**Table 5**
The most frequently reported culture media for L-ASNase production by SmF are Luria-Bertani (LB) medium, tryptone glucose yeast extract broth and modified Czapek-Dox medium with optimal pH ranging from 6.2 to 7.5, temperature from 28 to 37 ºC and fermentation times extending from 24 to 168 h depending upon the type of the employed microorganism (Dharmaraj 2011; Usha et al. 2011; Gurunathan and Renganathan 2012; Einsfeldt et al. 2016; Vimal and Kumar 2017; El-Naggar et al. 2018). Using LB broth as medium, a L-ASNase with an activity of 8.7 IU mg\(^{-1}\) and 23.85 IU mg\(^{-1}\) was obtained from \textit{Yersinia pseudotuberculosis YpA} and \textit{B. subtilis hswx88}, respectively (Pokrovskaya et al. 2012; Jia et al. 2013).

According to Singh et al. (2013), the production of L-ASNase from \textit{B. aryabhattai ITBH02} using M9 medium and L-Asparagine as nitrogen source, reached an enzymatic activity of 9.88 IU mg\(^{-1}\) with optimal temperature and pH of 40 ºC and 8.5, respectively (Singh et al. 2013). Using \textit{Serratia marcescens} and glycerol, peptone and yeast extract as medium, Sukumaran et al. (1979) recovered an enzyme with 2.4 IU mg\(^{-1}\) activity, optimal temperature of 37 ºC, optimal pH ranging from 6.8 to 7.0, and fermentation time of 24h (Sukumaran et al. 1979). Boyd and Phillips (1971) recovered an activity of 0.7 IU mg\(^{-1}\) at 26 ºC, pH of 5.0 and fermentation time of 40 h when studying the same enzyme from the same source (Boyd and Philips 1971). Erva et al. (2017) produced L-ASNase from \textit{Enterobacter aerogenes MTCC111} with an activity of 18.35 IU mL\(^{-1}\) applying trisodium citrate (0.75% (m/v)) and ammonium chloride (0.15% (m/v)) for 40 h at 33ºC (Erva et al. 2017). Reports from Gaffar and Shethna (1977) revealed a L-ASNase with a specific activity of 4 IU mg\(^{-1}\) when applying sucrose as carbon source at 30 ºC and pH of 7.4 (Gaffar and Shethna 1977). Using \textit{Emericella nidulans} to produce L-ASNase, Jayaramu et al. (2010) obtained a protein with an activity of 1.1 IU mL\(^{-1}\) with fermentation period of 48 h, at 30 ºC and pH of 6.0 (Jayaramu et al. 2010). These results indicate that each
potential producing strain requires its own specific conditions, and there are no established fixed parameters for SmF. Thus, specific optimization studies need to be performed after the microorganism selection.

As aforementioned, L-ASNase production by SmF from recombinant microbial strains, such as *E. coli*, has been employed aiming to meet the current market demand. However, as depicted at Table 5, there are several studies performed in SmF with other potential microorganisms that can result in high yields of L-ASNase and these enzymes can be applied in the food industry.

Considering SFF, it emerged as an alternative to SmF for the production of extracellular enzymes as it allows the direct use of crude fermented product as enzyme source and has the potential for the production of secondary metabolites (Lopes et al. 2017). Generally, this process uses cheap agriculture waste such as rice bran, wheat bran, sesame oil cake, corn cob, soybean meal, gram husk, coconut oil cake, groundnut cake and tea waste (Vimal and Kumar 2017). The use of agricultural wastes makes the procedure not only less cost effective but also it reduces the environmental pollution (Vimal and Kumar 2017). In this fermentation process, substrates are used slowly and steadily by the microorganism. That means the same substrate can be used for long fermentation periods (Nadu 2012). In fact, SSF is more relevant for fermentation processes involving fungi and microorganisms that require less moisture content. It does not suit fermentation processes involving organisms that require an high water activity, such as bacteria (Babu and Satyanarayana 1996; Nadu 2012). Additionality, this process offers benefits such as low energy and equipment requirement, cheaper growth substrates, and the downstream processes can be easier since the fermentation process can provide more concentrated solutions making concentrating unit operations unnecessary (Holker
and Lenz 2005). However, when compared with SmF, only few reports are available on SFF (Table 6) for the L-ASNase production.
### Table 6

Table 6. L-asparaginase production by solid-state culture at various operating condition

| Microorganism            | Culture medium         | Moisture (%)* | Temperature (ºC) | pH  | Cultivation period (h) | L-ASNase activity | Reference                      |
|--------------------------|------------------------|---------------|------------------|-----|------------------------|--------------------|--------------------------------|
| *Aspergillus niger*      | Soya bean meal         | 70            | 30               | 6.5 | 96                     | 40.9 IU g⁻¹       | (Mishra 2006)                  |
| *Aspergillus flavus*     | Orange peel            | 40            | 35               | 6   | 96                     | 339.16 IU g⁻¹     | (Rani et al. 2011)            |
| *Aspergillus terreus*    | Sesame oil cake (SOC)  | 40            | 30               | -   | 96                     | 68.49 IU g⁻¹      | (Suresh and Raju 2012)         |
| *Aspergillus terreus*    | Black gram husk (BH)   | 40            | 30               | -   | 96                     | 15.95 IU g⁻¹      | (Suresh and Raju 2012)         |
| *Aspergillus terreus*    | (SOC+BH) (7:3)         | 40            | 30               | -   | 96                     | 74.21 IU g⁻¹      | (Suresh and Raju 2012)         |
| *Aspergillus terreus*    | (SOC+BH) (7:3)         | 60            | 32               | 7   | 120                    | 163.34 IU g⁻¹     | (Suresh and Raju 2012)         |
| *Cladosporium sp.*       | Wheat bran             | -             | 30               | -   | 120                    | 0.096 IU g⁻¹      | (Mohan Kumar and Manonmani 2013) |
| *Fusarium solani* AUMC 8615 | Maltose               | 60            | 30               | 8   | -                      | 438.4 IU mL⁻¹     | (Isaac and Abu-Tahon 2016)     |
| Organism                        | Source                        | Water Mass (%) | Ubiquinone (%) | Solvent (%) | ILU/g       | Source                                    |
|--------------------------------|-------------------------------|----------------|----------------|-------------|------------|-------------------------------------------|
| *Fusarium equiseti*            | Soybean meal, glucose, yeast extract | -              | 45             | 7           | 48         | 3.26 IU mL⁻¹                              | (Hosamani and Kaliwal 2011a) |
| *Pseudomonas aeruginosa 50071* | Soya bean meal                | 50             | 37             | 7.4         | 96         | 1900 IU mg⁻¹                              | (El-Bessoumy et al. 2004)  |
| *Serratia marcescens (NCIM 2919)* | Sesame oil cake              | 68.64          | 37             | -           | 96         | 110.80 IU g⁻¹                             | (Ghosh et al. 2013)       |
| *Serratia marcescens (NCIM 2919)* | Coconut oil cake             | 40             | 35             | 6           | 24         | 3.87 IU g⁻¹                               | (Ghosh et al. 2013)       |
| *Serratia marcescens (NCIM 2919)* | Citrus limetta pulp          | 60             | 28             | 7.5         | 48         | 83.16 IU g⁻¹                              | (Kumar et al. 2011)       |
| *Serratia marcescens SB08*     | Rice bran                     | 50             | 30             | 7           | 36         | 79.84 IU g⁻¹                              | (Venil and Lakshmanaperumalsamy 2009) |

*: ratio of the water mass in the sample to the mass of solids in the sample.
Venil and Lakshmanaperumalsamy (2009) produced an L-ASNase with an activity of 79.84 IU g⁻¹ using a modified strain of *S. mercescens* grown in rice bran for 36 h with 50% moisture, at 30 °C and pH of 7.0 (Venil and Lakshmanaperumalsamy 2009). Suresh and Raju (2012) optimized the production of L-ASNase by SSF from *Aspergillus terreus* MTCC 1782 using different culture media, such as sesame oil cake (SOC), black gram husk (BH) and a mix of both, with temperature and moisture ranging from 30 °C to 32 °C, and 40% to 60%, respectively. The fermentation period ranged between 96 h and 120h. The optimal culture medium ended up being the mixture of SOC and BH (7:3), reaching an enzymatic activity of 163.34 IU g⁻¹, while using just black gram husk resulted in an enzyme with 15.95 IU g⁻¹ of activity (Suresh and Raju 2012). Reports from Mishra (2006) revealed an L-ASNase with an activity of 40.9 U g⁻¹ using bran of *Glycine max* with a 70% moisture for 96 h at 30°C and pH of 6.5 (Mishra 2006). On a similar study, El-Bessoumy et al. (2004) used soy bean meal as a culture medium with a 50% moisture during 96 h, at 37 °C and pH of 7.4 to produce an L-ASNase with an activity of 1900 IU mg⁻¹ from *Pseudomonas aeruginosa* 50071 (El-Bessoumy et al. 2004). Using a genetically modified fungi (*Aspergillus flavus* KUFS20), Rani et al. (2011) applied orange peel with a moisture of 40% during 96 h, at 35 °C and pH of 6.0 to reach an enzyme activity of 339.16 IU g⁻¹ (Rani et al. 2011).

*Operational conditions influencing L-Asparaginase production*

The optimum production period for L-ASNase from microbial sources varies from 24 to 72 h, depending on the microorganism employed. The lowest optimum cultivation time for production of this enzyme was reported in *Staphylococcus aureus* strain NCTC413 corresponding to a total of 10 h (Chand et al. 2020). On the other hand, among the analyzed studies, the highest optimum period for L-ASNase production bioprocess
was registered for *Spirulina maxima* with 432 h (18 days), which allowed to obtain an activity of 51.28 IU L$^{-1}$ (Abd El Baky and El Baroty 2016). Among the reported actinomycetes, the maximum enzyme production of 8.79 U mg$^{-1}$ was obtained after a culture period of 144 h for *Streptomyces brolohsae* NEAE-115 using dextrose starch as production medium (El-Naggar et al. 2018). Mesas et al. (1990) used *Corynebacterium glutamicum* to produce an L-ASNase with an activity of 20.6 IU mg$^{-1}$, value that did not change significantly with the time of cultivation suggesting that this enzyme might be constitutive in this strain (Mesas et al. 1990).

Besides the fermentation period, one of the most essential parameters in bioprocessing is the temperature. Optimum temperatures reported for L-ASNase production by most microorganisms ranged from 25 ºC to 37 ºC. In fact, cultivation temperature has a direct effect on the development of microorganisms and, consequently, affects the enzyme production and its activity (Ghosh et al. 2013). L-ASNase produced from *B. licheniformis* presented high enzyme yield (7.78 IU mL$^{-1}$) at an optimum temperature of 37 ºC, while increasing the temperature to 47 ºC results on a reduction in the enzyme activity up to 32.19% (Alrumman et al. 2019). Aside from this, the same microorganisms may have distinct optimum temperatures when supplied with different culture medium. Ghosh et al. (2013) demonstrated that *Serratia marcescens* NCIM 2919 incubated with *Citrus limetta* pulp showed an optimal temperature of 28 ºC, while when incubated with a medium made up of coconut oil cake and sesame oil cake revealed an optimal temperature of 35 ºC and 37 ºC, respectively, indicating once again the complexity of establishing an optimized industrial bioprocess (Ghosh et al. 2013). Nevertheless, there are organisms like *Streptomyces gulbargensis* and *Fusarium equiseti* with higher optimal temperatures (40 ºC and 45 ºC, respectively), which when applied to other enzymes results in lower production or lower activity (Amena et al. 2010; Hosamani
and Kaliwal 2011). These microorganisms (S. gulbargensis and F. equiseti) can be considered as sources to be explored further for production of heat-resistant L-ASNase for food processing.

The pH of the culture also affects the bioprocessing of the enzyme alongside the transport of several components across the cell membrane (Chand et al. 2020). The regulation of pH is indispensable while using carbon sources like glucose, fructose or mannitol once it decreases the pH of the medium. This drop occurs as a result of acid production in the fermentation process which leads to inhibition of L-ASNase production (Alrumman et al. 2019). Several studies report that the optimum pH to produce L-ASNase from bacterial sources is usually close to 7. According to Moorthy et al. (2010) and Nartel al. (2011), both Bacillus sp. and Bacillus brevis produced L-ASNases with maximal enzyme activity at pH 7.0, revealing a specific activity of 1 IU mg⁻¹ and 2.036 IU mg⁻¹, respectively (Moorthy et al. 2010, Nartel al. 2011). Prema et al. (2013) demonstrated that Pseudomonas fluorescens produced L-ASNase with an activity of 168.4 IU mL⁻¹ at an optimal pH of 8 (Prema et al. 2013). Regarding to the bacteria Vibrio succinogenes, Kafkewitz and Goodman (1974) revealed an optimal pH between 7.0 and 7.2 for L-ASNase production using succinate as medium, while Krautheim et al. (1982) demonstrated that using sodium fumarate and cysteine as medium the optimal pH is 7.2-7.3.

**Industrial developments to produce L-Asparaginase from microbial source**

Despite the growing demand for L-ASNase worldwide in the last decades, only a few commercial products have been widely spread throughout the market and are well stablished in major industries and biotechnology companies. Considering therapeutical applications, some of the most successful formulations for use against ALL are the native
E. coli L-ASNase - Elspar® (Merck & Co., Inc, USA), its pegylated form Oncaspar® (Sigma-Tau Pharmaceuticals, USA) and the E. chrysanthemi L-ASNase Erwinaze® (Jazz Pharmaceuticals, USA). These L-ASNase formulations have been already produced in several countries under different brand names, such as Medac® (Kyowa Hakko, Japan), and Crasnitin® (Bayer AG, Germany) (Shrivastava et al., 2016; Pieters et al., 2010).

Due to the increasing health concerning by authorities and industrialized food consumers, food industries have suffered pressure to offer healthier products. In that context, alternatives for prevention of acrylamide formation begin to emerge in the market. PreventASE™ from DSM (The Netherlands) is produced by Aspergillus niger and present indications to reduce up to 90% in acrylamide levels. The commercial product was released in the market in 2007 and present an acidic profile (optimum pH 4.0–5.0, temperature 50°C). Other often applied commercial L-ASNase is the branded Acrylaway® from Novozymes A/S (Denmark), obtained from Aspergillus oryzae, that presents neutral biochemical characteristics (optimum pH 7.0, temperature 37°C) (Xu et al., 2016).

Pedreschi et al. (2008) pioneered in publishing results using a commercial L-ASNase for food process purposes (Acrylaway®). The authors established that the optimum temperature and pH for this enzyme are 60°C and 7.0, respectively. In these conditions, it was reached a 67% reduction in acrylamide in tested french fries. The authors highlighted the importance of blanching and temperature control in the food treatment (Pedreschi et al. 2008). Hendriksen et al. (2009) reported the use of Acrylaway® and its effectiveness in a wide range of foods, e.g., gingerbread, crispbread, semi-sweet biscuits, french fries and crisps (Hendriksen et al. 2009). New similar products had been launched since then, such as Acrylaway® HighT in 2013 (Novozymes A/S, Denmark), an
enzyme specifically designed for higher temperature processing, expanding the applicability (Xu et al., 2016).

**Conclusion and future perspectives**

L-ASNase catalyzes the hydrolysis of L-Asparagine which is of high importance in healthcare and food industries. The enzyme is naturally produced by a high number of microorganisms; nevertheless, only a few provide enough enzyme with the desired and improved biochemical properties that makes them commercially and economically viable. Microbial L-ASNases are different from each other in terms of biochemical parameters such as optimal pH and temperature, molecular weight, kinetic properties and stability. Currently, *E. coli* and *E. chrysanthemi* genes are the main sources of the commercial L-ASNase. However, both enzymes face the challenge of resilient immunogenicity and clinical resistance, which consequently affect its application. Thus, L-ASNases from new sources stand out as promising alternatives. However, their use faces several obstacles, such as enzyme activity, kinetic parameters, thermal and storage stability, characteristics that diverge from the optimal for establishing applicable and feasible bioprocesses. Still, sources such as *A. flavus*, marine *Actinomycetes*, *P. aeruginosa* and recombinant *Bacillus* show promising characteristics for industrial production. Moreover, studies in bioreactor are still required aiming to improve L-ASNase yields from potential novel sources. Following to the wide application and importance of L-ASNase preparations, further studies should be conducted in order to reduce production costs, adverse reactions and clinical side effects.

**Acknowledgments**
This work was developed within the scope of the project CICECO-Aveiro Institute of Materials, UIDB/50011/2020 & UIDP/50011/2020, financed by national funds through the Portuguese Foundation for Science and Technology/MCTES. This work was also financially supported by the project POCI-01-0145-FEDER-031268, funded by FEDER, through COMPETE2020 - Programa Operacional Competitividade e Internacionalização (POCI), and by national funds (OE), through FCT/MCTES. A.P.M. Tavares acknowledges FCT for the Investigator Programme and Exploratory Project (IF/01634/2015) with financing from the European Social Fund and the Human Potential Operational Programme. Valéria C. Santos-Ebinuma, Danielle B. Pedrolli, Gabriela B. de Paiva and Heitor B. S. Bento acknowledge FAPESP, CNPq (National Council for Scientific and Technological Development, Brazil) and CAPES (Coordination of Superior Level Staff Improvement, Brazil).

**Author’s contributions**

DC, MRA, MGF, APMT and VCSE: designed and lead the writing process, DC, ASM GBP, HBSB, DBP, MRA and VCSE jointly performed the literature search and wrote the manuscript. All authors read and approved the manuscript.

**Compliance with Ethical Standards**

**Funding:** This work was funded by the project CICECO-Aveiro Institute of Materials, UIDB/50011/2020 & UIDP/50011/2020, financed by national funds through the Portuguese Foundation for Science and Technology/MCTES, by FEDER, through COMPETE2020 - Programa Operacional Competitividade e Internacionalização (POCI) and by national funds (OE), through FCT/MCTES (POCI-01-0145-FEDER-031268), by the FCT Investigator Programme and Exploratory Project (IF/01634/2015), by FAPESP
(2018/06908-8, 2020/15513-7), and the CAPES (Coordination of Superior Level Staff Improvement, Brazil), finance code 001.

**Conflict of interest:** The authors declare that they have no conflict of interest.

**Ethical approval.** This article does not contain any studies with human participants or animals performed by the author

**References**

Abd El Baky HH, El Baroty GS (2016) Optimization of growth conditions for purification and production of L-asparaginase by *Spirulina maxima*. Evidence-Based Complement Altern Med 2016:

Abdelrazek NA, Elkhatib WF, Raafat MM, Aboulwafa MM (2020) Production, characterization and bioinformatics analysis of l-asparaginase from a new *Stenotrophomonas maltophilia* EMCC2297 soil isolate. AMB Express 10:1–16

Aghaiypour, K., Wlodawer, A., & Lubkowski, J. (2001). Structural basis for the activity and substrate specificity of *Erwinia chrysanthemi* L-asparaginase. Biochemistry, 40(19), 5655-5664.

Aishwarya SS, Selvarajan E, Iyappan S, Rajnish KN (2019) Recombinant l-Asparaginase II from *Lactobacillus casei* subsp. casei ATCC 393 and Its Anticancer Activity. Indian J Microbiol 59:313–320. https://doi.org/10.1007/s12088-019-00806-0

Alrumman SA, Mostafa YS, Al-izran KA, Alfaifi MY, Taha TH, Elbehairi SE (2019) Production and Anticancer Activity of an L-Asparaginase from *Bacillus licheniformis* Isolated from the Red Sea, Saudi Arabia. Sci Rep 9:1–14 . https://doi.org/10.1038/s41598-019-40512-x

Amena S, Vishalakshi N, Mujagond P, A D, Lingappa K (2010) Production, purification and characterization of L-asparaginase from *Streptomyces gulbargensis*. Brazilian J Microbiol
Angélica ME, Evangelista-Martínez Z, González-Mondragón EG, Calderón-Flores A, Arreguín R, Pérez-Rueda E, Huerta-Saquero A (2012) Biochemical characterization of recombinant L-asparaginase (AnsA) from *Rhizobium etli*, a member of an increasing Rhizobial-type family of L-asparaginases. J Microbiol Biotechnol 22:292–300 .
https://doi.org/10.4014/jmb.1107.07047

Asha A, Pallavi B (2012) Production, purification and characterization of Extracellular L-asparaginase having antineoplastic activity from *Fusarium* sp. J adv Res Biol Sci 4:293–301

Asselin B, Gelber R, Sallan S (1995) Relative toxicity of *E-coli* L-asparaginase (ASP) and pegasparcase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL). Blood 86:695

Babu KR, Satyanarayana T (1996) Production of bacterial enzymes by solid state fermentation. J Sci Ind Res 55:464–467

Batool T, Makky EA, Jalal M, Yusoff MM (2016) A Comprehensive Review on l-Asparaginase and Its Applications. Appl Biochem Biotechnol 178:900–923 .
https://doi.org/10.1007/s12010-015-1917-3

Borah D, Yadav RNS, Sangra A, Shahin L, Chaubey A (2012) Production, purification and process optimization of asparaginase (an anticancer enzyme) from *E. coli*, isolated from sewage water. Asian J Pharm Clin Res 5:202–204

Borek D, Jaskólski M (2001) Sequence analysis of enzymes with asparaginase activity. Acta Biochim Pol 48:893–902

Boyd JW, Phillips AW (1971) Purification and properties of L-asparaginase from *Serratia marcescens*. J Bacteriol 106:578–587

Brumano LP, da Silva FVS, Costa-Silva TA, Apolinário AC, Santos JHPM, Kleingesinds EK, Monteiro G, Rangel-Yagui C de O, Benyahia B, Junior AP, Vitor F (2019) Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles. Front Bioeng Biotechnol 6:1–22 .
Buchholz K, Kasche V, Bornscheuer UT (2012) Biocatalysts and enzyme technology. John Wiley & Sons

Chand S, Mahajan R V., Prasad JP, Sahoo DK, Mihooliya KN, Dhar MS, Sharma G (2020) A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications. Biotechnol Appl Biochem. https://doi.org/10.1002/bab.1888

Chityala S, Venkata Dasu V, Ahmad J, Prakasham RS (2015) High yield expression of novel glutaminase free l-asparaginase II of Pectobacterium carotovorum MTCC 1428 in Bacillus subtilis WB800N. Bioprocess Biosyst Eng 38:2271–2284 . https://doi.org/10.1007/s00449-015-1464-x

Chohan SM, Rashid N (2013) TK1656 , a thermostable L-asparaginase from Thermococcus kodakaraensis , exhibiting highest ever reported enzyme activity. J Biosci Bioeng 116:438–443 . https://doi.org/10.1016/j.jbiosc.2013.04.005

Chohan SM, Sajed M, un Naeem S, Rashid N (2020) Heterologous gene expression and characterization of TK2246, a highly active and thermostable plant type l-asparaginase from Thermococcus kodakaraensis. Int J Biol Macromol

Choi B, Rempala GA, Kim JK (2017) Beyond the Michaelis-Menten equation: Accurate and efficient estimation of enzyme kinetic parameters. Sci Rep 7:1–11

Corrêa GC, Lins MRCR, Silva BF, de Paiva GB, Zocca VFB, Ribeiro NV, Picheli FP, Mack M, Pedrolli DB (2020) A modular autoinduction device for control of gene expression in Bacillus subtilis. Metab Eng 61:326-334. https://doi.org/10.1016/j.ymben.2020.03.012

Costa IM, Schultz L, de Araujo Bianchi Pedra B, Leite MS, Farsky SH, de Oliveira MA, Pessoa A, Monteiro G (2016) Recombinant L-asparaginase 1 from Saccharomyces cerevisiae: an allosteric enzyme with antineoplastic activity. Sci Rep 6:36239. https://doi.org/10.1038/srep36239

Cristovão RO, Almeida MR, Barros MA, Nunes JCF, Boaventura RAR, Loureiro JM, Faria JL, Neves MC, Freire MG, Santos-Ebinuma VC, Tavares APM, Silva CG (2020) Development and characterization of a novel Lasparaginase/MWCNT nanobioconjugate. RSC Adv.
Daniel RM, Peterson ME, Danson MJ, Price NC, Kelly SM, Monk CR, Weinberg CS, Oudshoorn ML, Lee CK (2010) The molecular basis of the effect of temperature on enzyme activity. Biochem J 425:353–360

De Oliveira F, Ferreira LC, Baptista Neto A, Teixeira MFS, Santos-Ebinuma VC (2020) Biosynthesis of natural colorants by Talaromyces amestolkiae: Mycelium accumulation and colorant formation in incubator shaker and in bioreactor. Biochem Eng J 161:107694. https://doi.org/10.1016/j.bej.2020.107694

Derst C, Henseling J, Röhm KH (2000) Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 9:2009–2017. https://doi.org/10.1110/ps.9.10.2009

Dharmaraj S (2011) Study of L-asparaginase production by Streptomyces noursei MTCC 10469, isolated from marine sponge Callyspongia diffusa. Iran J Biotechnol 9:102–108

Dias FFG, Ruiz ALTG, Torre A Della, Sato HH (2016) Purification, characterization and antiproliferative activity of l-asparaginase from Aspergillus oryzae CCT 3940 with no glutaminase activity. Asian Pac J Trop Biomed 6:785–794. https://doi.org/https://doi.org/10.1016/j.apjtb.2016.07.007

Dhevagi, P., Poorani, E. (2006). Isolation and characterization of L-asparaginase from marine actinomycetes. Indian J. Biotechnol. 5:514-520.

Doriya K, Jose N, Gowda M, Kumar DS (2016) Solid-State Fermentation vs Submerged Fermentation for the Production of L-Asparaginase. Adv Food Nutr Res 78:115–135. https://doi.org/10.1016/bs.afnr.2016.05.003

Dunlop PC, Roon RJ (1975) L-Asparaginase of Saccharomyces cerevisiae: an extracellular Enzyme. J Bacteriol 122:1017 LP--1024

Dutta S, Roy R, Lahiri D (2015) L-asparaginase and l-glutaminase from Pseudomonas aeruginosa: production and some physicochemical properties. J Microbiol Biotechnol Food Sci 05:34–39. https://doi.org/10.15414/jmbfs.2015.5.1.34-39

Ebrahiminezhad, A., Rasoul-Amini, S., Ghoshoon, M.B., Ghasemi, Y. 2014. Chlorella vulgaris,
A Novel Microalgal Source For L-Asparaginase Production. Biocatalysis And Agricultural Biotechnology, 3 (2), 214–217.

Einsfeldt K, Baptista IC, Pereira JCCV, Costa-Amaral IC, Da Costa ES, Ribeiro MCM, Land MGP, Alves TLM, Larentis AL, Almeida RV (2016) Recombinant L-Asparaginase from *zymomonas mobilis*: A potential new antileukemic agent produced in *Escherichia coli*. PLoS One 11:1–18. https://doi.org/10.1371/journal.pone.0156692

El-Bessoumy A, Sarhan M, Mansour J (2004) Production, Isolation, and Purification of L-Asparaginase from *Pseudomonas Aeruginosa* 50071 Using Solid-state Fermentation. J Biochem Mol Biol 37:387–393. https://doi.org/10.5483/BMBRep.2004.37.4.387

El-Naggar NE-A, Deraz SF, El-Ewasy SM, Suddek GM (2018) Purification, characterization and immunogenicity assessment of glutaminase free L-asparaginase from *Streptomyces brollosae* NEAE-115. BMC Pharmacol Toxicol 19:51

El-naggar NE, El-shweihy NM (2020) Bioprocess development for L-asparaginase production by *Streptomyces rochei*, purification and in-vitro efficacy against various human carcinoma cell lines. Sci Rep 1–21. https://doi.org/10.1038/s41598-020-64052-x

Elshafei, A. M.; Hassan, M. M.; Ali, N. H.; Abouzeid, M. A. E.; Mahmoud, D. A.; Elghonemy DH (2014) Purification, kinetic properties and antitumor activity of L-glutaminase from *Penicillium brevicompactum* NRC 829. Br Microbiol Res J 2:158–174

Erva RR, Goswami AN, Suman P, Vedanabhatla R, Rajulapati SB (2017) Optimization of L-asparaginase production from novel *Enterobacter* sp., by submerged fermentation using response surface methodology. Prep Biochem Biotechnol 47:219–228

Farag AM, Hassan SW, Beltagy EA, El-Shenawy MA (2015) Optimization of production of anti-tumor l-asparaginase by free and immobilized marine *Aspergillus terreus*. Egypt J Aquat Res 41:295–302. https://doi.org/https://doi.org/10.1016/j.ejar.2015.10.002

Farahat MG, Amr D, Galal A (2020) Molecular cloning, structural modeling and characterization of a novel glutaminase-free L-asparaginase from *Cobetia amphilecti* AM16. Int J Biol Macromol 143:685–695

Faret M, de Morais SB, Zanchin NIT, de Souza T de ACB (2019) l-Asparaginase from *Erwinia*
*carotovora*: insights about its stability and activity. Mol Biol Rep 46:1313–1316.
https://doi.org/10.1007/s11033-018-4459-2

Feng Y, Liu S, Jiao Y, Gao H, Wang M, Du G, Chen J (2017) Enhanced extracellular production of L-asparaginase from *Bacillus subtilis* 168 by B. subtilis WB600 through a combined strategy. Appl Microbiol Biotechnol 101:1509–1520.
https://doi.org/10.1007/s00253-016-7816-x

Fisher SH, Wray L V. (2002) *Bacillus subtilis* 168 contains two differentially regulated genes encoding L-asparaginase. J Bacteriol 184:2148–2154.
https://doi.org/10.1128/JB.184.8.2148-2154.2002

Foda MS, Zedan HH, Hashem SA (1980) Formation and properties of L-glutaminase and L-asparaginase activities in *Pichia polymorpha*. Acta Microbiol Pol 29:343–352

Gaffar SA, Shethna YI (1977) Purification and some biological properties of asparaginase from *Azotobacter vinelandii*. Appl Environ Microbiol 33:508–514

Gamboa-Suasnavart RA, Marfn-Palacio LD, Martínez-Sotelo JA, Espitia C, Servín-González L, Valdez-Cruz NA, Trujillo-Roldán MA (2013) Scale-up from shake flasks to bioreactor, based on power input and *Streptomyces lividans* morphology, for the production of recombinant APA (45/47 kDa protein) from *Mycobacterium tuberculosis*. World J Microbiol Biotechnol 29:1421–1429. https://doi.org/10.1007/s11274-013-1305-5

Gervais D, Foote N (2014) Recombinant Deamidated Mutants of *Erwinia chrysanthemii*-Asparaginase Have Similar or Increased Activity Compared to Wild-Type Enzyme. Mol Biotechnol 56:865–877. https://doi.org/10.1007/s12033-014-9766-9

Ghosh S, Murthy S, Govindasamy S, Chandrasekaran M (2013) Optimization of L-asparaginase production by *Serratia marcescens* (NCIM 2919) under solid state fermentation using coconut oil cake. Sustain Chem Process 1:9. https://doi.org/10.1186/2043-7129-1-9

Goswami R, Veeranki VD, Mishra VK (2019) Optimization of process conditions and evaluation of pH & thermal stability of recombinant l-Asparaginase II of *Erwinia carotovora* subsp. atroseptica SCRI 1043 in E. coli. Biocatal Agric Biotechnol 22:101377. https://doi.org/10.1016/j.bcab.2019.101377
Gurunathan DB, Renganathan (2012) Optimization of L-asparaginase production by *Aspergillus terreus* MTCC 1782 using response surface methodology and artificial neural network linked genetic algorithm. Asia-Pacific J Chem Eng 7: . https://doi.org/10.1002/apj.520

Hendriksen, H. V., Kornbrust, B. A., Østergaard, P. R., Stringer, M. A. (2009). Evaluating the potential for enzymatic acrylamide mitigation in a range of food products using an asparaginase from *Aspergillus oryzae*. Journal of agricultural and food chemistry, 57(10):4168-4176.

Holker U, Lenz J (2005) Solid-state fermentation - are they any biotechnological advantages? Curr Opin Microbiol 8:301-306. https://doi.org/10.1016/j.mib.2005.04.006

Hong S, Lee Y, Khan AR, Ullah I, Lee C, Park CK, Shin J (2014) Cloning, expression, and characterization of thermophilic L-asparaginase from *Thermococcus kodakarenensis* KOD1. J Basic Microbiol 54:500–508

Hosamani R, Kaliwal BB (2011a) Isolation, molecular identification and optimization of fermentation parameters for the production of L-asparaginase, an anticancer agent by *Fusarium equiseti*. Int J Microbiol Res 3:108

Husain I, Sharma A, Kumar S, Malik F (2016) Purification and characterization of glutaminase free asparaginase from *Pseudomonas otitidis*: Induce apoptosis in human leukemia MOLT-4 cells. Biochimie 121:38–51 . https://doi.org/10.1016/j.biochi.2015.11.012

Isaac GS, Abu-Tahon MA (2016) Production of extracellular anti-leukemic enzyme L-asparaginase from *Fusarium solani* AUMC 8615 grown under solid-state fermentation conditions: purification and characterization of the free and immobilized enzyme. Egypt J Bot 56:799–816

Izadpanah F, Homaei A, Fernandes P, Javadpour S (2018) Marine microbial L-asparaginase: Biochemistry, molecular approaches and applications in tumor therapy and in food industry. Microbiol Res 208:99–112 . https://doi.org/10.1016/j.micres.2018.01.011

Javier J, Cachumba M, Antonio F, Antunes F, Fernando G, Peres D, Brumano LP, César J, Santos D, Silvério S, Silva D (2016) Current applications and different approaches for microbial L-asparaginase production. Brazilian J Microbiol 47:77–85 .
Jayaramu M, Hemalatha NB, Rajeshwari CP, Siddalingeshwara KG, Mohsin SM, Dutt PS (2010) A novel approach for detection, confirmation and optimization of L-asparaginase from Emericella nidulans. J Curr Pharma Res 1:20

Jia M, Xu M, He B, Rao Z (2013) Cloning, expression, and characterization of L-asparaginase from a newly isolated Bacillus subtilis B11-06. J Agric Food Chem 61:9428–9434.

Jiao L, Chi H, Lu Z, Zhang C, Chia SR, Show PL, Tao Y, Lu F (2020) Characterization of a novel type I L-asparaginase from Acinetobacter soli and its ability to inhibit acrylamide formation in potato chips. J Biosci Bioeng 129:672–678.

Kafkewitz D, Goodman D (1974) L-Asparaginase production by the rumen anaerobe Vibrio succinogenes. Appl Microbiol 27:206–209

Kavitha A, Vijayalakshmi M (2012) A study on L-asparaginase of Nocardia levis MK-VL_113. Sci World J 2012:

Khushoo A, Pal Y, Singh BN, Mukherjee KJ (2004) Extracellular expression and single step purification of recombinant Escherichia coli L-asparaginase II. Protein Expr Purif 38:29–36

Kidd JG (1953) Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 98:565–582.

Kil J-O, Kim G-N, Park I (1995) Extraction of Extracellular L-Asparaginase from Candida utilis. Biosci Biotechnol Biochem 59:749–750. https://doi.org/10.1271/bbb.59.749

Kishore V, Nishita KP, Manonmani HK (2015) Cloning, expression and characterization of L-asparaginase from Pseudomonas fluorescens for large scale production in E. coli BL21. 3 Biotech 5:975–981. https://doi.org/10.1007/s13205-015-0300-y

Kotzia GA, Labrou NE (2005) Cloning, expression and characterisation of Erwinia carotovora
Kotzia GA, Labrou NE (2007) L-Asparaginase from *Erwinia Chrysanthemi* 3937: cloning, expression and characterization. J Biotechnol 127:657–669. https://doi.org/10.1016/j.jbiotec.2006.07.037

Kozak M, Jurga S (2002) A comparison between the crystal and solution structures of *Escherichia coli* asparaginase II. 49:

Krautheim P, Greenstein T, Kafkewitz D (1982) Asparaginase production by chemostat cultures of *Vibrio succinogenes*. FEMS Microbiol Lett 13:105–107

Krishnapura PR, Belur PD, Subramanya S (2016) A critical review on properties and applications of microbial l-asparaginases. Crit Rev Microbiol 42:720–737. https://doi.org/10.3109/1040841X.2015.1022505

Kumar DP, Thangabalan B, Venkata RM, Vadivel K, Manohar BS, Rao DS (2011) Optimization of parameters for the production of L-asparaginase by *Serratia marcescens*. J Pharm Biomed Sci 7:20

Kumar DS, Sobha K (2012) L-Asparaginase from Microbes: a Comprehensive Review. Adv Biores 3:

Kumar S, Kalimuthu V, Sivaram V (2020) A Study on Production and Evaluation of L-Asparaginase Obtained From *Bacillus Subtilis*

Kumar S, Prabhu AA, Dasu VV, Pakshirajan K (2017) Batch and fed-batch bioreactor studies for the enhanced production of glutaminase-free L-asparaginase from *Pectobacterium carotovorum* MTCC 1428. Prep Biochem Biotechnol 47:74–80.

https://doi.org/10.1080/10826068.2016.1168841

Li X, Zhang X, Xu S, Zhang H, Xu M, Yang T, Wang L, Qian H, Zhang H, Fang H, Osire T, Rao Z, Yang S (2018) Simultaneous cell disruption and semi-quantitative activity assays for high-throughput screening of thermostable L-asparaginases. Sci Rep 8:7915.

https://doi.org/10.1038/s41598-018-26241-7

Lima GM, Effer B, Biasoto HP, Feijoli V, Pessa A, Palmisano G, Monteiro G (2020) Glycosylation of L-asparaginase from *E. coli* through yeast expression and site-directed
mutagenesis. Biochem Eng J 156:107516.

https://doi.org/https://doi.org/10.1016/j.bej.2020.107516

Lopes AM, de Oliveira-Nascimento L, Ribeiro A, Tairum CA, Breyer CA, de Oliveira MA, Monteiro G, de Souza-Motta CM, Magalhães P de O, Avendaño JGF, Cavaco-Paulo AM, Mazzola PG, Rangel-Yagui C de O, Sette LD, Converti A, Pessoa A (2017) Therapeutic L-asparaginase: upstream, downstream and beyond. Crit Rev Biotechnol 37:82–99.
https://doi.org/10.3109/07388551.2015.1120705

Lopes W, Santos BAF dos, Sampaio ALF, Gregório Alves Fontão AP, Nascimento HJ, Jurgilas PB, Torres FAG, Bon EP da S, Almeida RV, Ferrara MA (2019) Expression, purification, and characterization of asparaginase II from Saccharomyces cerevisiae in Escherichia coli. Protein Expr Purif 159:21–26. https://doi.org/https://doi.org/10.1016/j.pep.2019.02.012

Lubkowski, J., Dauter, M., Aghaiypour, K., Wlodawer, A., & Dauter, Z. (2003). Atomic resolution structure of Erwinia chrysanthemi L-asparaginase. Acta Crystallographica Section D: Biological Crystallography, 59(1), 84-92.

Luhana K, Dave A, Patel K (2013) Production, purification and characterization of extracellular L-asparaginase (Anti Cancerous Enzyme) from Aspergillus Niger. Int J Chemtech Appl 2:14–25

Mahajan R V, Kumar V, Rajendran V, Saran S, Ghosh PC, Saxena RK (2014) Purification and Characterization of a Novel and Robust L-Asparaginase Having Low-Glutaminase Activity from Bacillus licheniformis: In Vitro Evaluation of Anti-Cancerous Properties. PLoS One 9:e99037

Maqsood B, Basit A, Khurshid M, Bashir Q (2020) Characterization of a thermostable, allosteric L-asparaginase from Anoxybacillus flavithermus. Int J Biol Macromol 152:584-592. doi: 10.1016/j.ijbiomac.2020.02.246.

Mashburn LT, Wriston JC (1964) Tumor inhibitory effect of L-Asparaginase from Escherichia coli. Arch Biochem Biophys 105:450–452. https://doi.org/10.1016/0003-9861(64)90032-3

Meena B, Anburajan L, Sathish T, Vijaya Raghavan R, Dharani G, Valsalan Vinithkumar N,
Kirubagaran R (2015) L-Asparaginase from *Streptomyces griseus* NIOT-VKMA29: optimization of process variables using factorial designs and molecular characterization of L-asparaginase gene. Sci Rep 5:12404 . https://doi.org/10.1038/srep12404

Meena B, Anburajan L, Vinithkumar NV, Shridhar D, Raghavan RV, Dharani G, Kirubagaran R (2016) Molecular expression of L-asparaginase gene from *Nocardiopsis alba* NIOT-VKMA08 in *Escherichia coli*: A prospective recombinant enzyme for leukaemia chemotherapy. Gene 590:220–226 . https://doi.org/10.1016/j.gene.2016.05.003

Mesas JM, Gil JA, Martin JF (1990) Characterization and partial purification of L-asparaginase from *Corynebacterium glutamicum*. Microbiology 136:515–519

Michalska K, Jaskolski M (2006) Structural aspects of L-asparaginases, their friends and relations. Acta Biochim Pol 53:627–640

Mihooliya KN, Nandial J, Kumari A, Nanda S, Verma H, Sahoo DK (2020) Studies on efficient production of a novel L-asparaginase by a newly isolated *Pseudomonas resinovorans* IGS-131 and its heterologous expression in *Escherichia coli*. 3 Biotech 10:148 . https://doi.org/10.1007/s13205-020-2135-4

Mishra A (2006) Production of L-asparaginase, an anticancer agent, from *Aspergillus niger* using agricultural waste in solid state fermentation. Appl Biochem Biotechnol 135:33–42

Moguel IS (2018) Production of L-asparaginase of pharmaceutical interest from yeasts isolated from the Antarctic continent

Mohan Kumar NS, Manonmani HK (2013) Purification, characterization and kinetic properties of extracellular L-asparaginase produced by *Cladosporium* sp. World J Microbiol Biotechnol 29:577–587 . https://doi.org/10.1007/s11274-012-1213-0

Moola ZB, Scawen MD, Atkinson T, Nicholls DJ (1994) *Erwinia chrysanthemi* L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 302 (Pt 3):921–927 . https://doi.org/10.1042/bj3020921

Moorthy, V; Ramalingam, A; Sumantha (2010) Production, purification and characterisation of extracellular L-asparaginase from a soil isolate of *Bacillus* sp. African J Microbiol Res 4:1862–1867
Müller HJ, Boos J (1998) Use of L-asparaginase in childhood all. Crit Rev Oncol Hematol 28:97–113. https://doi.org/10.1016/S1040-8428(98)00015-8

Muneer F, Siddique MH, Azeem F, Rasul I, Muzammil S, Zubair M, Afzal M, Nadeem H (2020) Microbial l-asparaginase: purification, characterization and applications. Arch Microbiol. https://doi.org/10.1007/s00203-020-01814-1

Muslim SN (2014) Production, purification and characterization of a novel l-asparaginase from Acinetobacter baumannii with anticancerous activity. Int J Curr Eng Technol 4:

Nadu T (2012) Solid State and Submerged Fermentation for the Production of Bioactive Substances: a Comparative Study. 3:480–486

Narta U, Roy S, Kanwar SS, Azmi W (2011) Improved production of L-asparaginase by Bacillus brevis cultivated in the presence of oxygen-vectors. Bioresour Technol 102:2083–2085

Nguyen HA, Su Y, Lavie A (2016) Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity. J Biol Chem 291:17664–17676. https://doi.org/10.1074/jbc.M116.728485

Nunes JCF, Cristovão RO, Freire MG, Santos-Ebinuma VC, Faria J, Silva CG, Tavares APM (2020) Recent Strategies and Applications for l-Asparaginase Confinement. Molecules 25:5827 doi:10.3390/molecules25245827

Ollenschläger G, Roth E, Linkesch W, Jansen S, Simmel A, Mödder B (1988) Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 18:512–516. https://doi.org/10.1111/j.1365-2362.1988.tb01049.x

Orabi HM, El-Fakharany EM, Abdelkhalek ES, Sidkey NM (2019) L-Asparaginase and L-glutaminase: Sources, production, and applications in medicine and industry. J Microbiol Biotechnol Food Sci 179–190. https://doi.org/10.15414/jmfs.2019.9.2.179-190

Patro KR, Gupta N (2012) Extraction, purification and characterization of L-asparaginase from Penicillium sp. by submerged fermentation. Int J Biotechnol Mol Biol Res 3:30–34. https://doi.org/10.5897/ijbmbrr11.066
Paul JH (1982) Isolation and characterization of a Chlamydomonas l-asparaginase. Biochem J 203:109–115. https://doi.org/10.1042/bj2030109

Pedreschi, F., Kaack, K., Granby, K. (2008). The effect of asparaginase on acrylamide formation in French fries. Food Chemistry, 109(2), 386–392.

Peterson RE, Ciegler A (1969) L-asparaginase production by Erwinia aroideae. Appl Microbiol 18:64–67

Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH (2011) L-asparaginase treatment in acute lymphoblastic leukemia. Cancer 117:238–249. https://doi.org/10.1002/cncr.25489

Pokrovskaya M V, Aleksandrova SS, Pokrovsky VS, Omeljanjuk NM, Borisova AA, Anisimova NY, Sokolov NN (2012) Cloning, expression and characterization of the recombinant Yersinia pseudotuberculosis L-asparaginase. Protein Expr Purif 82:150–154

Prema P, Devi MN, Alagumanikumaran N (2013) Production of tumor inhibitory L-asparaginase by wild and mutant strains of Pseudomonas fluorescens. Int J Adv Res 1:163–171

Pui C-H, Liu Y, Relling M V (2018) How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer 65:. https://doi.org/10.1002/pbc.26884

Qeshmi, F. I., Homaei, A., Fernandes, P., & Javadpour, S. (2018). Marine microbial L-asparaginase: biochemistry, molecular approaches and applications in tumor therapy and in food industry. Microbiological research, 208, 99-112. https://doi.org/10.1016/j.micres.2018.01.011

Radha R, Arumugam N, Gummadi SN (2018) Glutaminase free l-asparaginase from Vibrio cholerae: Heterologous expression, purification and biochemical characterization. Int J Biol Macromol 111:129–138.

https://doi.org/https://doi.org/10.1016/j.ijbiomac.2017.12.165

Radha R, Gummadi SN (2020) Optimisation of physical parameters pH and temperature for maximised activity and stability of Vibrio cholerae L-asparaginase by statistical experimental design. Indian Chem Eng 1–10
Rani SA, Sundaram L, Vasantha BP (2011) In vitro antioxidant and anticancer activity of L-asparaginase from *Aspergillus flavus* (KUFS20). Asian J Pharm Clin Res 4:174–177

Rodrigues D, Pillaca-Pullo O, Torres-Obreke K, Flores-Santos J, Sánchez-Moguel I, Pimenta M V, Basi T, Converti A, Lopes AM, Monteiro G, Fonseca LP, Pessoa AJ (2019) Fed-Batch Production of *Saccharomyces cerevisiae* L-Asparaginase II by Recombinant *Pichia pastoris* MUTs Strain . Front. Bioeng. Biotechnol. 7:16

Rudrapati P, Audipudi A V (2015) Characterization and bioprocessing of oncolytic enzyme–L-asparaginase isolated from marine *bacillus* AVP 14. Int J Pharm Sci Rev Res 30:195–201

Saeed H, Ali H, Soudan H, Embaby A, El-Sharkawy A, Farag A, Hussein A, Ataya F (2018a) Molecular cloning, structural modeling and production of recombinant *Aspergillus terreus* L. asparaginase in *Escherichia coli*. Int J Biol Macromol 106:1041–1051 .
https://doi.org/10.1016/j.ijbiomac.2017.08.110

Saeed H, Hemida A, El-Nikhely N, Abdel-Fattah M, Shalaby M, Hussein A, Eldoksh A, Ataya F, Aly N, Labrou N, Nematalla H (2020) Highly efficient *Pyrococcus furiosus* recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines. Int J Biol Macromol 156:812–828 .
https://doi.org/https://doi.org/10.1016/j.ijbiomac.2020.04.080

Saeed H, Soudan H, El-Sharkawy A, Farag A, Embaby A, Ataya F (2018b) Expression and Functional Characterization of *Pseudomonas aeruginosa* Recombinant l.Asparaginase. Protein J 37:461–471 . https://doi.org/10.1007/s10930-018-9789-3

Safary A, Moniri R, Hamzeh-Mivehrourd M, Dastmalchi S (2019) Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant *Bacillus* strain. Bioimpacts 9:15–23 . https://doi.org/10.15171/bi.2019.03

Sajitha S, Vidya J, Varsha karunakaran, Binod P, Pandey A (2015) Cloning and expression of l-asparaginase from *E. coli* in eukaryotic expression system. Biochem Eng J 102:14–17 .
https://doi.org/https://doi.org/10.1016/j.bej.2015.02.027

Saleem Basha N, Rekha R, Komala M, Ruby S (2009) Production of extracellular anti-
leukaemic enzyme L-asparaginase from marine actinomycetes by solid-state and submerged fermentation: Purification and characterisation. Trop J Pharm Res 8:353–360 .
https://doi.org/10.4314/tjpr.v8i4.45230

Santos JHPM, Costa IM, Molino JVD, Leite MSM, Pimenta M V, Coutinho JAP, Pessoa Jr A, Ventura SPM, Lopes AM, Monteiro G (2017) Heterologous expression and purification of active L-asparaginase I of Saccharomyces cerevisiae in Escherichia coli host. Biotechnol Prog 33:416–424 . https://doi.org/10.1002/btpr.2410

Santos NV, Santos-Ebinuma VC, Pessoa Junior A, Pereira JFB (2018) Liquid–liquid extraction of biopharmaceuticals from fermented broth: trends and future prospects. J Chem echnol Biotechnol 93: 1845–1863. https://doi.org/10.1002/jctb.5476

Sarquis MI de M, Oliveira EMM, Santos AS, da Costa GL (2004) Production of L-asparaginase by filamentous fungi. Mem Inst Oswaldo Cruz 99:489–492 .
https://doi.org/10.1590/S0074-02762004000500005

Savitri, Asthana N, Azmi W (2003) Microbial L-asparaginase: A potent antitumour enzyme. Indian J Biotechnol 2:184–194

Saxena, A., Upadhyay, R., & Kango, N. (2015). Isolation and identification of actinomycetes for production of novel extracellular glutaminase free L-asparaginase. Ind. J. Exp. Biol, 53:786-793.

Shakambari G, Sameer Kumar R, Ashokkumar B, Ganesh V, Vasantha VS, Varalakshmi P (2018) Cloning and expression of L-asparaginase from Bacillus tequilensis PV9W and therapeutic efficacy of Solid Lipid Particle formulations against cancer. Sci Rep 8:18013 .
https://doi.org/10.1038/s41598-018-36161-1

Sharma D, Singh K, Singh K, Mishra A (2018) Insights into the Microbial L-Asparaginases: from Production to Practical Applications. Curr Protein Pept Sci 20:452–464 .
https://doi.org/10.2174/1389203720666181114111035

Shi R, Liu Y, Mu Q, Jiang Z, Yang S (2017) Biochemical characterization of a novel L-asparaginase from Paenibacillus barengoltzii being suitable for acrylamide reduction in potato chips and mooncakes. Int J Biol Macromol 96:93–99 .
Shrivastava, A., Khan, A. A., Khurshid, M., Kalam, M. A., Jain, S. K., & Singhal, P. K. (2016). Recent developments in l-asparaginase discovery and its potential as anticancer agent. Critical reviews in oncology/hematology, 100, 1-10.

Sindhu R, Manonmani HK (2018a) Expression and characterization of recombinant l-asparaginase from Pseudomonas fluorescens. Protein Expr Purif 143:83–91

Sindhu R, Manonmani HK (2018b) Protein Expression and Purification Expression and characterization of recombinant L-asparaginase from Pseudomonas fluorescens. Elsevier Ltd

Singh Y, Gundampati RK, Jagannadham M V, Srivastava SK (2013) Extracellular L-asparaginase from a protease-deficient Bacillus aryabhattai ITBHU02: purification, biochemical characterization, and evaluation of antineoplastic activity in vitro. Appl Biochem Biotechnol 171:1759–1774

Singh Y, Srivastava S (2012) Screening and Characterization of Microorganisms Capable of Producing Antineoplastic Drug, L-asparaginase. Int J Biol Med Res 3:2548–2554

Steckel J, Roberts J, Philips FS, Chou T-C (1983) Kinetic properties and inhibition of Acinetobacter glutaminase-asparaginase. Biochem Pharmacol 32:971–977

Sukumaran CP, Singh D V, Mahadevan PR (1979) Synthesis of L-asparaginase by Serratia marcescens (Nima). J Biosci 1:263–269

Suresh J V, Raju KJ (2012) Studies on the production of L-asparaginase by Aspergillus terreus MTCC 1782 using agro-residues under mixed substrate solid state fermentation. J Chem Biol Phys Sci 3:314

Susan Aishwarya S, Iyappan S, Vijaya Lakshmi K, Rajnish KN (2017) In silico analysis, molecular cloning, expression and characterization of l-asparaginase gene from Lactobacillus reuteri DSM 20016. 3 Biotech 7:348. https://doi.org/10.1007/s13205-017-0974-4

Sushma C, Anand AP, Veeranki VD (2017) Enhanced production of glutaminase free L-asparaginase II by Bacillus subtilis WB800N through media optimization. Korean J Chem
Torres FAE, Zaccarim BR, de Lencastre Novaes LC, Jozala AF, Santos CA dos, Teixeira MFS, Santos-Ebinuma VC (2016) Natural colorants from filamentous fungi. Appl Microbiol Biotechnol 100:2511–2521. https://doi.org/10.1007/s00253-015-7274-x

Usha R, Mala KK, Venil CK, Palaniswamy M (2011) Screening of actinomycetes from mangrove ecosystem for L-asparaginase activity and optimization by response surface methodology. Polish J Microbiol 60:213–221

Vala AK, Sachaniya B, Dudhagara D, Panseriya HZ, Gosai H, Rawal R, Dave BP (2018) Characterization of L-asparaginase from marine-derived Aspergillus niger AKV-MKBU, its antiproliferative activity and bench scale production using industrial waste. Int J Biol Macromol 108:41–46. https://doi.org/10.1016/j.ijbiomac.2017.11.114

Venil C, Lakshmanaperumalsamy P (2009) Solid state fermentation for production of L-asparaginase in rice bran by Serratia marcescens SB08. Internet J Microbiol 7:1

Vimal A, Kumar A (2017) Biotechnological production and practical application of L-asparaginase enzyme. Biotechnol Genet Eng Rev 33:40–61. https://doi.org/10.1080/02648725.2017.1357294

Xu, F., Oruna-Concha, M. J., & Elmore, J. S. (2016). The use of asparaginase to reduce acrylamide levels in cooked food. Food chemistry, 210, 163-171.

Yano S, Minato R, Thongsanit J, Tachiki T, Wakayama M (2008) Overexpression of type I L-asparaginase of Bacillus subtilis in Escherichia coli, rapid purification and characterisation of recombinant type I L-asparaginase. Ann Microbiol 58:711–716. https://doi.org/10.1007/BF03175579

Yao, M., Yasutake, Y., Morita, H., & Tanaka, I. (2005). Structure of the type I L-asparaginase from the hyperthermophilic archaeon Pyrococcus horikoshii at 2.16 Å resolution. Acta Crystallographica Section D: Biological Crystallography, 61(3), 294-301.

Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H, Sako M, Tsujino G, Inada Y (1986) Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res 77:1264—
Zhang S, Xie Y, Zhang C, Bie X, Zhao H, Lu F, Lu Z (2015) Biochemical characterization of a novel l-asparaginase from *Bacillus megaterium* H-l and its application in French frites. Food Res Int 77:527–533.

Zuo S, Xue D, Zhang T, Jiang B, Mu W (2014) Biochemical characterization of an extremely thermostable l-asparaginase from *Thermococcus gammatolerans* EJ3. J Mol Catal B Enzym 109:122–129. https://doi.org/10.1016/j.molcatb.2014.08.021